

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 August 2001 (09.08.2001)

PCT

(10) International Publication Number
WO 01/57024 A1

(51) International Patent Classification⁷: C07D 405/04,
231/14, 413/04, 409/04, 417/04, 417/14, 401/12, 231/56,
A61K 31/415, 31/416, 31/4155, A61P 25/00, C07D
403/04

The Cruciform Building, Gower Street, London WC1E
6AU (GB). WISHART, Grant [GB/GB]; University
College London, The Wolfson Institute for Biomedical
Research, The Cruciform Building, Gower Street, London
WC1E 6AU (GB).

(21) International Application Number: PCT/GB01/00472

(22) International Filing Date: 5 February 2001 (05.02.2001)

(74) Agent: WOODS, Geoffrey, Corlett; J.A. Kemp & Co., 14
South Square, Gray's Inn, London WC1R 5LX (GB).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0002666.6 4 February 2000 (04.02.2000) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except US*): UNI-
VERSITY COLLEGE LONDON [GB/GB]; Gower
Street, London WC1E 9BT (GB).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): GARTHWAITE,
Gitti [GB/GB]; University College London, The Wolf-
son Institute for Biomedical Research, The Cruciform
Building, Gower Street, London WC1E 6AU (GB). SEL-
WOOD, David [GB/GB]; University College London,
The Wolfson Institute for Biomedical Research, The
Cruciform Building, Gower Street, London WC1E 6AU
(GB). KLING, Marcel [AU/GB]; University College
London, The Wolfson Institute for Biomedical Research,


Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 01/57024 A1

(54) Title: BLOCKADE OF VOLTAGE DEPENDENT SODIUM CHANNELS



(57) Abstract: Compounds of formula (I), and pharmaceutically acceptable salts thereof, are capable of blocking voltage-dependent sodium channels and are useful in particular, in treating glaucoma and multiple sclerosis.

BLOCKADE OF VOLTAGE DEPENDENT SODIUM CHANNELS

The present invention relates to a series of pyrazole and indazole compounds capable of blockading voltage dependent sodium channels. Voltage-dependent sodium channels are found in the cell membranes of neurones (including their axons) where they are fundamental to the generation and propagation of electrical impulses. Under pathological conditions (such as ischaemia), however, sodium channels become abnormally activated resulting in an excessive flow of sodium ions into the cytoplasm. The rise in cellular sodium ions then causes a large inflow of calcium ions leading to the activation of several mechanisms that lead to irreversible loss of function and subsequent degeneration (Taylor, C.P. & Meldrum, B.S. (1995), *Trends Pharmacol. Sci.* 16, 309-316 and Urenjak J. & Obrenovitch, T.P. (1996), *Pharmacol. Rev.* 48, 21-67).

It has already proved possible to produce pharmacological agents capable of stopping excessive activity of sodium channels without adversely affecting their normal function. Indeed, this is the principal mode of action of several widely-used and well-tolerated antiepileptic drugs (e.g. phenytoin, carbamazepine and lamotrigine). Sodium channel inhibitors have been shown to be protective towards neurones in the grey matter in several models of cerebral ischaemia (Taylor, C.P. & Meldrum, B.S. (1995), *Trends Pharmacol. Sci.* 16, 309-316 and Urenjak J. & Obrenovitch, T.P. (1996), *Pharmacol. Rev.* 48, 21-67). More recently, it has become evident that certain sodium channel inhibitors are highly effective in protecting axons in the *in vitro* optic nerve from irreversible damage imposed by severe deprivation of oxygen and glucose (Stys, P.K. (1998), *J. Cereb. Blood Flow Metab* 18, 2-25 & Garthwaite et al (1999), *Neuroscience*, 94, 1219-1230).


It has now, surprisingly, been found that a series of specific pyrazole and indazole compounds are capable of inhibiting voltage dependent sodium channels. They can achieve a highly effective protective action on white matter, or myelin coated nerve cell fibres. Such a neuroprotective effect on ganglion cells and axons can lead to valuable therapeutic benefits.

-2-

Certain pyrazoles and indazoles are known *per se*. Thus, 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1) is known as an activator of soluble guanylate cyclase (Hobbs, A.J., *TIPS*, December 1997, Vol 18, p.484). Further, EP-A-667345 discloses a number of indazole analogues of YC-1 as inhibitors of platelet aggregation.

DE-A-19642323 discloses a number of 1-benzyl-indazole compounds for use in treating circulation disorders and DE-A-19642255 discloses similar compounds for use as vasodilators.

The present invention provides the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in blocking voltage-dependent sodium channels



wherein:

- R₁ is hydrogen, C₁-C₆ alkyl, aryl or -(C₁-C₆ alkyl)-aryl;
- R₂ is aryl, heteroaryl, 3- to 6- membered heterocyclyl, C₃-C₆ carbocyclyl or -XR wherein X is a divalent C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl group and R is aryl, heteroaryl, 3- to 6- membered heterocyclyl or C₃-C₆ carbocyclyl, or R₂ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or -COR, -CONR'R'' or -CO₂R' wherein each R' and R'' is the same or different and is selected from hydrogen, C₁-C₆ alkyl, aryl and heteroaryl and R is selected from C₁-C₆ alkyl, aryl and heteroaryl; and
- either R₃ and R₄, together with the carbon atoms to which they are attached, form a phenyl group, or R₃ and R₄ are the same or different and are selected from hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, heteroaryl, 3- to 6-membered heterocyclyl, -COR, -CONR'-NR''COR, -CONR'-NR''CS-R, -CO₂R', -CONR'-NR''-CO₂R', -CONR'-NR''-CS-OR', -CONR'R'', -CONR'-NR''CO-NR'''R'''' and -CONR'-NR''CS-NR'''R''''', wherein each R is the same or different and is selected

-3-

from C₁-C₆ alkyl, aryl, -(C₁-C₆ alkyl)-aryl and heteroaryl and each R', R'', R''' and R'''' is the same or different and is selected from hydrogen, C₁-C₆ alkyl, aryl, -(C₁-C₆ alkyl)-aryl and heteroaryl.

Typically,

- 5 - R₁ is hydrogen, C₁-C₆ alkyl, aryl or -(C₁-C₆ alkyl)-aryl;
- R₂ is aryl, heteroaryl, 3- to 6- membered heterocyclyl, C₃-C₆ carbocyclyl or -XR wherein X is a divalent C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl group and R is aryl, heteroaryl, 3- to 6- membered heterocyclyl or C₃-C₆ carbocyclyl, or R₂ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or -COR, -CONR'R''
- 10 or -CO₂R' wherein each R' and R'' is the same or different and is selected from hydrogen, C₁-C₆ alkyl and aryl and R is selected from C₁-C₆ alkyl or aryl; and
- either R₃ and R₄, together with the carbon atoms to which they are attached, form a phenyl group, or R₃ and R₄ are the same or different and are selected from hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, heteroaryl, 3- to 6-
- 15 membered heterocyclyl, -COR, -CONR'-NR''COR, -CONR'-NR''CS-R, -CO₂R', -CONR'-NR''-CO₂R', -CONR'-NR''-CS-OR', -CONR'R'', -CONR'-NR''CO-NR'''R'''' and -CONR'-NR''CS-NR'''R''''', wherein each R is the same or different and is selected from C₁-C₆ alkyl and aryl and each R', R'', R''' and R'''' is the same or different and is selected from hydrogen, C₁-C₆ alkyl and aryl.

20 As used herein, a C₁-C₆ alkyl group or moiety is a linear or branched alkyl group or moiety. Suitable such alkyl groups and moieties include C₁-C₄ alkyl groups and moieties, for example methyl, ethyl, n-propyl, i-propyl, n-butyl and t-butyl. Methyl, ethyl, n-butyl and t-butyl are preferred.

 A C₁-C₆ alkyl group or moiety can be unsubstituted or substituted at any

25 position. Typically, it is unsubstituted or carries one or two substituents. Suitable substituents include halogen, cyano, nitro, hydroxy, C₁-C₆ alkoxy, for example methoxy, and -NR'R'' wherein R' and R'' are the same or different and represent hydrogen or C₁-C₆ alkyl. Preferred substituents are halogen, NMe₂, NHEt, NH₂ and OMe. Further, a haloalkyl group is a preferred substituted alkyl group.

30 As used herein, a C₂-C₆ alkenyl group or moiety can be linear or branched.

-4-

Suitable such alkenyl groups and moieties include C₂-C₄ alkenyl groups and moieties such as ethenyl, propenyl or butenyl.

A C₂-C₆ alkenyl group or moiety can be unsubstituted or substituted at any position. Typically, it is unsubstituted or carries one or two substituents. Suitable
5 substituents include halogen, cyano, nitro, hydroxy, C₁-C₆ alkoxy, for example methoxy, and -NR'R'' wherein R' and R'' are the same or different and represent hydrogen or C₁-C₆ alkyl. Preferred substituents are halogen, NMe₂, NHEt, NH₂ and OMe.

As used herein, a C₂-C₆ alkynyl group or moiety can be linear or branched.
10 Suitable such alkynyl groups and moieties include C₂-C₄ alkynyl groups and moieties such as ethynyl, propynyl and butynyl. An alkynyl group or moiety can be unsubstituted or substituted at any position. Typically, it is unsubstituted or carries one or two substituents. Suitable substituents include halogen, cyano, nitro, hydroxy, C₁-C₆ alkoxy, for example methoxy, and -NR'R'' wherein R' and R'' are the same or
15 different and represent hydrogen or C₁-C₆ alkyl. Preferred substituents are halogen, NMe₂, NHEt, NH₂ and OMe.

A -(C₁-C₆ alkyl)-aryl group is typically a said C₁-C₆ alkyl group joined to an aryl group, as defined below. It is preferably benzyl or -ethyl-phenyl.

A halogen atom is typically a chlorine, fluorine, bromine or iodine atom. It is
20 preferably chlorine or fluorine.

As used herein, an aryl group or moiety is typically a C₆-C₁₀ aryl group or moiety. Suitable such aryl groups and moieties include phenyl and naphthyl. Phenyl is preferred.

An aryl group or moiety may be substituted or unsubstituted at any position.
25 Typically, it is unsubstituted or carries 1, 2, 3 or 4 substituents. Suitable substituents include halogen, hydroxyl, -SH, C₁-C₆ alkyl, for example -CF₃ and -CCl₃, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, heteroaryl, 3- to 6- membered heterocyclyl, C₃-C₆ carbocyclyl, -XY wherein X is a divalent C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl group and Y is an aryl or heteroaryl group, nitro, cyano, C₁-C₆ alkoxy, C₂-C₆
30 alkenyloxy, C₂-C₆ alkynyloxy, C₁-C₆ alkylthio, C₂-C₆ alkenylthio, C₂-C₆ alkynylthio,

-5-

-OR, -SR, -COR', -CO₂R'', -CONR'''R''', -NR'''R'''' and -NR''-CO-R' wherein R is aryl, heteroaryl or -XY wherein X is a divalent C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl group and Y is an aryl or heteroaryl group, R' is selected from R, C₁-C₆ alkyl, C₂-C₆ alkenyl and C₂-C₆ alkynyl, R'' is selected from R' and hydrogen and R''' and R'''' are the same or different and are selected from R', hydrogen and hydroxy. Further suitable substituents include -S-X-COR, -O-X-COR, -S-X-CO₂R and -O-X-CO₂R wherein X is a divalent C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl group and R is C₁-C₆ alkyl, aryl or heteroaryl.

Preferred substituents include halogen, for example chlorine, fluorine and bromine, -SH, hydroxy, C₁-C₆ alkyl, for example t-butyl, methyl, -CF₃, -CCl₃, -CH₂OH, -CH₂NMe₂, -CH₂NH₂ and -(CH₂)₃OMe, aryl, heteroaryl, 3- to 6- membered heterocyclyl, C₃-C₆ carbocyclyl, -(C₁-C₆ alkyl)-aryl, -(C₁-C₆ alkyl)-heteroaryl, nitro, cyano, C₁-C₆ alkoxy, C₂-C₆ alkenyloxy, C₂-C₆ alkynyloxy, C₁-C₆ alkylthio, C₂-C₆ alkenylthio, C₂-C₆ alkynylthio, -OR, -SR, -COR', -CO₂R'', -CONR'''R''', -NR'''R'''' and -NR''-CO-R' wherein R is aryl or -(C₁-C₆ alkyl)-aryl, R' is selected from R or C₁-C₆ alkyl, R'' is selected from R' and hydrogen and R''' and R'''' are the same or different and are selected from R', hydrogen and hydroxy, -S-(C₁-C₆ alkyl)-CO-R and -S-(C₁-C₆ alkyl)-CO₂R, wherein R is aryl or C₁-C₆ alkyl. Typically, these preferred substituents are selected from halogen, for example chlorine, fluorine and bromine, -SH, hydroxy, C₁-C₆ alkyl, for example t-butyl, methyl, -CF₃, -CCl₃, -CH₂OH, -CH₂NMe₂, -CH₂NH₂ and -(CH₂)₃OMe, aryl, heteroaryl, 3- to 6- membered heterocyclyl, C₃-C₆ carbocyclyl, nitro, cyano, C₁-C₆ alkoxy, C₂-C₆ alkenyloxy, C₁-C₆ alkylthio, C₂-C₆ alkenylthio, -OR, -SR, -COR', -CO₂R'', -CONR'''R'''' and -NR'''R'''' wherein R is aryl or -(C₁-C₆ alkyl)-aryl, R' is selected from R or C₁-C₆ alkyl, R'' is selected from R' and hydrogen and R''' and R'''' are the same or different and are selected from R', hydrogen and hydroxy, and -S-(C₁-C₆ alkyl)-CO-R, wherein R is aryl or C₁-C₆ alkyl.

More preferred substituents include halogen, for example fluorine, chlorine and bromine, -SH, hydroxy, C₁-C₆ alkyl, for example, methyl, ethyl, propyl, n-butyl, t-butyl, -CF₃, -CCl₃, -CH₂OH, -CH₂NMe₂, -CH₂NH₂ and -(CH₂)₃OMe, aryl, for

example phenyl, heteroaryl, for example oxazolyl and pyridyl, C₃-C₆ carbocyclyl, for example cyclohexane, -(C₁-C₆ alkyl)-aryl, for example -CH₂-(4-methoxyphenyl), -C₁-C₆ alkoxy, C₂-C₆ alkenyloxy, C₂-C₆ alkynyloxy, C₁-C₆ alkylthio, for example methylthio and ethylthio, C₂-C₆ alkenylthio, for example ethenylthio and propenylthio, C₂-C₆ alkynylthio, for example propynylthio, -O-aryl, for example -O-phenyl, -O-(C₁-C₆ alkyl)-aryl, for example -O-(CH₂)-phenyl, -CO₂H, -CO₂-(C₁-C₆ alkyl), for example -CO₂Me and -CO₂Et, -CONH-aryl, for example -CONH-phenyl, -CONH-OH, -CONH-(C₁-C₆ alkyl), for example -CONH(CH₂)₂NMe₂, -CON(OH)-(C₁-C₆ alkyl)-aryl, for example -CON(OH)-CH₂-phenyl, NR'R'' wherein R' and R'' are the same or different and are hydrogen or C₁-C₆ alkyl, for example NH₂, NMe₂ and NH₂Et, -NH-CO-(C₁-C₆ alkyl), for example -NH-CO-Me, -S-(C₁-C₆ alkyl)-aryl for example -S-CH₂-phenyl, -S-(C₁-C₆ alkyl)-CO-R and -S-(C₁-C₆ alkyl)-CO₂R wherein R is aryl, for example phenyl, or C₁-C₆ alkyl, for example ethyl or t-butyl. Typically, these more preferred substituents are selected from halogen, for example fluorine, chlorine and bromine, -SH, hydroxy, C₁-C₆ alkyl, for example, methyl, ethyl, propyl, n-butyl, t-butyl, -CF₃, -CCl₃, -CH₂OH, -CH₂NMe₂, -CH₂NH₂ and -(CH₂)₃OMe, aryl, for example phenyl, C₃-C₆ carbocyclyl, for example cyclohexane, C₁-C₆ alkoxy, C₂-C₆ alkenyloxy, C₁-C₆ alkylthio, for example methylthio and ethylthio, C₂-C₆ alkenylthio, for example ethenylthio and propenylthio, -CO₂H, -CO₂-(C₁-C₆ alkyl), for example -CO₂Me and -CO₂Et, -CONH-aryl, for example -CONH-phenyl, -CONH-OH, -CONH-(C₁-C₆ alkyl), for example -CONH(CH₂)₂NMe₂, -CON(OH)-(C₁-C₆ alkyl)-aryl, for example -CON(OH)-CH₂-phenyl, NR'R'' wherein R' and R'' are the same or different and are hydrogen or C₁-C₆ alkyl, for example NH₂, NMe₂ and NH₂Et, -S-(C₁-C₆ alkyl)-aryl for example -S-CH₂-phenyl, and -S-(C₁-C₆ alkyl)-CO-R wherein R is aryl, for example phenyl, or C₁-C₆ alkyl, for example ethyl or t-butyl.

Particularly preferred substituents are halogen, for example chlorine, fluorine and bromine, C₁-C₆ alkyl, for example -CF₃, methyl and t-butyl, C₁-C₆ alkoxy, for example methoxy, aryl, for example phenyl, heteroaryl, for example oxazolyl and pyridyl, C₃-C₆ cycloalkyl, for example cyclohexane, aryloxy, for example phenyloxy, -(C₁-C₆ alkyl)-aryl, for example -CH₂-(4-methoxyphenyl), -O-(C₁-C₆ alkyl)-aryl, for

-7-

example benzyloxy, -NMe₂, -CONH-aryl, for example -CONH-phenyl, and -NH-CO-(C₁-C₆ alkyl), for example -NH-CO-Me. Typically, these particularly preferred substituents are selected from halogen, for example chlorine, fluorine and bromine, C₁-C₆ alkyl, for example -CF₃, methyl and t-butyl, aryl, for example phenyl, and C₃-C₆ cycloalkyl, for example cyclohexane.

An aryl group or moiety may optionally be fused to a further said aryl group or moiety or to a carbocyclic, heterocyclic or heteroaryl group or moiety.

As used herein, a carbocyclic group or moiety is a non-aromatic, saturated or unsaturated hydrocarbon ring having from 3 to 6 carbon atoms. Preferably it is a saturated hydrocarbon ring (i.e. a cycloalkyl group) having from 3 to 6 carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. It is preferably cyclohexyl.

A carbocyclic group may be unsubstituted or substituted at any position. Typically, it is unsubstituted or carries up to 3 substituents. Suitable substituents include halogen, hydroxyl, -SH, C₁-C₆ alkyl, for example -CF₃ and -CCl₃, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryl, heteroaryl, 3- to 6- membered heterocyclyl, C₃-C₆ carbocyclyl, nitro, cyano, C₁-C₆ alkoxy, C₂-C₆ alkenyloxy, C₂-C₆ alkynyloxy, C₁-C₆ alkylthio, C₂-C₆ alkenylthio, C₂-C₆ alkynylthio, -OR, -SR, -COR', -CO₂R'', -CONR'''R'''' and -NR'''R'''' wherein R is aryl, heteroaryl or -XY wherein X is a divalent C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl group and Y is an aryl or heteroaryl group, R' is selected from R, C₁-C₆ alkyl, C₂-C₆ alkenyl and C₂-C₆ alkynyl, R'' is selected from R' and hydrogen and R''' and R'''' are the same or different and are selected from R', hydrogen and hydroxy. Further suitable substituents include -S-X-COR and -O-X-COR, wherein X is a divalent C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl group and R is aryl or heteroaryl.

Preferred substituents include halogen, for example chlorine, fluorine and bromine, -SH, hydroxy, C₁-C₆ alkyl, for example t-butyl, methyl, -CF₃, -CCl₃, -CH₂OH, -CH₂NMe₂, -CH₂NH₂ and -(CH₂)₃OMe, aryl, heteroaryl, 3- to 6- membered heterocyclyl, C₃-C₆ carbocyclyl, nitro, cyano, C₁-C₆ alkoxy, C₂-C₆ alkenyloxy, C₁-C₆ alkylthio, C₂-C₆ alkenylthio, -OR, -SR, -COR', -CO₂R'', -CONR'''R'''' and -NR'''R''''

-8-

wherein R is aryl or $-(C_1-C_6 \text{ alkyl})$ -aryl, R' is selected from R or C_1-C_6 alkyl, R'' is selected from R' and hydrogen and R''' and R'''' are the same or different and are selected from R' , hydrogen and hydroxy, and $-S-(C_1-C_6 \text{ alkyl})-CO-R$, wherein R is aryl or C_1-C_6 alkyl.

- 5 More preferred substituents include halogen, for example fluorine, chlorine and bromine, $-SH$, hydroxy, C_1-C_6 alkyl, for example, methyl, ethyl, propyl, n-butyl, t-butyl, $-CF_3$, $-CCl_3$, $-CH_2OH$, $-CH_2NMe_2$, $-CH_2NH_2$ and $-(CH_2)_3OMe$, aryl, for example phenyl, C_3-C_6 carbocyclyl, for example cyclohexane, C_1-C_6 alkoxy, C_2-C_6 alkenyloxy, C_1-C_6 alkylthio, for example methylthio and ethylthio, C_2-C_6 alkenylthio, 10 for example ethenylthio and propenylthio, $-CO_2H$, $-CO_2-(C_1-C_6 \text{ alkyl})$, for example $-CO_2Me$ and $-CO_2Et$, $-CONH$ -aryl, for example $-CONH$ -phenyl, $-CONH-OH$, $-CONH-(C_1-C_6 \text{ alkyl})$, for example $-CONH(CH_2)_2NMe_2$, $-CON(OH)-(C_1-C_6 \text{ alkyl})$ -aryl, for example $-CON(OH)-CH_2$ -phenyl, $NR'R''$ wherein R' and R'' are the same or different and are hydrogen or C_1-C_6 alkyl, for example NH_2 , NMe_2 and $NHEt$, $-S-(C_1-$ 15 $C_6 \text{ alkyl})$ -aryl for example $-S-CH_2$ -phenyl, and $-S-(C_1-C_6 \text{ alkyl})-CO-R$ wherein R is aryl, for example phenyl, or C_1-C_6 alkyl, for example ethyl or t-butyl.

As used herein, a heteroaryl group or moiety is typically a 5- to 10-membered aromatic ring, for example a 5- or 6- membered ring, containing at least one heteroatom selected from O, S and N. Examples include pyrrolyl, furanyl, 20 thienyl, oxadiazolyl and triazolyl. Further examples include isoxazolyl and pyridyl. Preferred heteroaryl groups are furanyl, oxadiazolyl, isoxazolyl, pyridyl and triazolyl groups. Typically, these preferred heteroaryl groups are selected from furanyl, oxadiazolyl and triazolyl groups.

- A heteroaryl group or moiety may be unsubstituted or substituted at any 25 position. Typically, it is unsubstituted or carries 1, 2 or 3 substituents. Suitable substituents include halogen, hydroxyl, $-SH$, C_1-C_6 alkyl, for example $-CF_3$ and $-CCl_3$, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, 3- to 6- membered heterocyclyl, C_3-C_6 carbocyclyl, $-XY$ wherein X is a divalent C_1-C_6 alkyl, C_2-C_6 alkenyl or C_2-C_6 alkynyl group and Y is an aryl or heteroaryl group, nitro, cyano, C_1-C_6 alkoxy, C_2-C_6 alkenyloxy, C_2-C_6 alkynyloxy, C_1-C_6 alkylthio, C_2-C_6 alkenylthio, C_2-C_6 alkynylthio, 30

-9-

-OR, -SR, -COR', -CO₂R'', -CONR'''R''', -NR'''R''' and -NR''-CO-R' wherein R is aryl, heteroaryl or -XY wherein X is a divalent C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl group and Y is an aryl or heteroaryl group, R' is selected from R, C₁-C₆ alkyl, C₂-C₆ alkenyl and C₂-C₆ alkynyl, R'' is selected from R' and hydrogen and R''' and R''' are the same or different and are selected from R', hydrogen and hydroxy. Further suitable substituents include -S-X-COR, -O-X-COR, -S-X-CO₂R and -O-X-CO₂R, wherein X is a divalent C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl group and R is C₁-C₆ alkyl, aryl or heteroaryl.

Preferred substituents include halogen, for example chlorine, fluorine and bromine, -SH, hydroxy, C₁-C₆ alkyl, for example t-butyl, methyl, -CF₃, -CCl₃, -CH₂OH, -CH₂NMe₂, -CH₂NH₂ and -(CH₂)₃OMe, aryl, heteroaryl, 3- to 6- membered heterocyclyl, C₃-C₆ carbocyclyl, -(C₁-C₆ alkyl)-aryl, -(C₁-C₆ alkyl)-heteroaryl, nitro, cyano, C₁-C₆ alkoxy, C₂-C₆ alkenyloxy, C₂-C₆ alkynyloxy, C₁-C₆ alkylthio, C₂-C₆ alkenylthio, C₂-C₆ alkynylthio, -OR, -SR, -COR', -CO₂R'', -CONR'''R''', -NR'''R''' and -NR''-CO-R' wherein R is aryl or -(C₁-C₆ alkyl)-aryl, R' is selected from R or C₁-C₆ alkyl, R'' is selected from R' and hydrogen and R''' and R''' are the same or different and are selected from R', hydrogen and hydroxy, -S-(C₁-C₆ alkyl)-CO-R and -S-(C₁-C₆ alkyl)-CO₂-R, wherein R is aryl or C₁-C₆ alkyl. Typically, these preferred substituents are selected from halogen, for example chlorine, fluorine and bromine, -SH, hydroxy, C₁-C₆ alkyl, for example t-butyl, methyl, -CF₃, -CCl₃, -CH₂OH, -CH₂NMe₂, -CH₂NH₂ and -(CH₂)₃OMe, aryl, heteroaryl, 3- to 6- membered heterocyclyl, C₃-C₆ carbocyclyl, nitro, cyano, C₁-C₆ alkoxy, C₂-C₆ alkenyloxy, C₁-C₆ alkylthio, C₂-C₆ alkenylthio, -OR, -SR, -COR', -CO₂R'', -CONR'''R''', -NR'''R''' wherein R is aryl or -(C₁-C₆ alkyl)-aryl, R' is selected from R or C₁-C₆ alkyl, R'' is selected from R' and hydrogen and R''' and R''' are the same or different and are selected from R', hydrogen and hydroxy, and -S-(C₁-C₆ alkyl)-CO-R, wherein R is aryl or C₁-C₆ alkyl.

More preferred substituents include halogen, for example fluorine, chlorine and bromine, -SH, hydroxy, C₁-C₆ alkyl, for example, methyl, ethyl, propyl, n-butyl, t-butyl, -CF₃, -CCl₃, -CH₂OH, -CH₂NMe₂, -CH₂NH₂ and -(CH₂)₃OMe, aryl, for

-10-

example phenyl, heteroaryl, for example oxazolyl and pyridyl, C₃-C₆ carbocyclyl, for example cyclohexane, -(C₁-C₆ alkyl)-aryl, for example -CH₂-(4-methoxyphenyl), C₁-C₆ alkoxy, C₂-C₆ alkenyloxy, C₂-C₆ alkynyloxy, C₁-C₆ alkylthio, for example methylthio and ethylthio, C₂-C₆ alkenylthio, for example ethenylthio and propenylthio, C₂-C₆ alkynylthio, for example propynylthio, O-aryl, for example -O-phenyl, -O-(C₁-C₆ alkyl)-aryl, for example -O-(CH₂)-phenyl, -CO₂H, -CO₂-(C₁-C₆ alkyl), for example -CO₂Me and -CO₂Et, -CONH-aryl, for example -CONH-phenyl, -CONH-OH, -CONH-(C₁-C₆ alkyl), for example -CONH(CH₂)₂NMe₂, -CON(OH)-(C₁-C₆ alkyl)-aryl, for example -CON(OH)-CH₂-phenyl, NR'R'' wherein R' and R'' are the same or different and are hydrogen or C₁-C₆ alkyl, for example NH₂, NMe₂ and NHEt, -NH-CO-(C₁-C₆ alkyl), for example -NH-CO-Me, -S-(C₁-C₆ alkyl)-aryl for example -S-CH₂-phenyl, -S-(C₁-C₆ alkyl)-CO-R and -S-(C₁-C₆ alkyl)-CO₂-R, wherein R is aryl, for example phenyl, or C₁-C₆ alkyl, for example ethyl or t-butyl. Typically, these more preferred substituents are selected from halogen, for example fluorine, chlorine and bromine, -SH, hydroxy, C₁-C₆ alkyl, for example, methyl, ethyl, propyl, n-butyl, t-butyl, -CF₃, -CCl₃, -CH₂OH, -CH₂NMe₂, -CH₂NH₂ and -(CH₂)₃OMe, aryl, for example phenyl, C₃-C₆ carbocyclyl, for example cyclohexane, C₁-C₆ alkoxy, C₂-C₆ alkenyloxy, C₁-C₆ alkylthio, for example methylthio and ethylthio, C₂-C₆ alkenylthio, for example ethenylthio and propenylthio, -CO₂H, -CO₂-(C₁-C₆ alkyl), for example -CO₂Me and -CO₂Et, -CONH-aryl, for example -CONH-phenyl, -CONH-OH, -CONH-(C₁-C₆ alkyl), for example -CONH(CH₂)₂NMe₂, -CON(OH)-(C₁-C₆ alkyl)-aryl, for example -CON(OH)-CH₂-phenyl, NR'R'' wherein R' and R'' are the same or different and are hydrogen or C₁-C₆ alkyl, for example NH₂, NMe₂ and NHEt, -S-(C₁-C₆ alkyl)-aryl for example -S-CH₂-phenyl, and -S-(C₁-C₆ alkyl)-CO-R wherein R is aryl, for example phenyl, or C₁-C₆ alkyl, for example ethyl or t-butyl.

Particularly preferred substituents include C₁-C₆ alkyl, for example -CH₂OH, -CH₂NH₂, -(CH₂)₃OMe, -CH₂NMe₂, t-butyl and methyl, halogen, for example chlorine, -SH, hydroxy, aryl, for example phenyl, C₃-C₆ carbocyclyl, for example cyclohexane, heteroaryl, for example oxadiazolyl and pyridyl, aryloxy, for example

-11-

phenyloxy, $-(C_1-C_6 \text{ alkyl})\text{-aryl}$, for example $-\text{CH}_2\text{-(4-methoxyphenyl)}$, $-\text{O-(C}_1\text{-C}_6\text{ alkyl)-aryl}$, for example benzyloxy, $C_1\text{-C}_6$ alkoxy, $C_2\text{-C}_6$ alkenyloxy, $C_2\text{-C}_6$ alkynyloxy, $C_1\text{-C}_6$ alkylthio, for example methylthio, $C_2\text{-C}_6$ alkenylthio, for example propenylthio, $C_2\text{-C}_6$ alkynylthio, for example propynylthio, $-\text{NMe}_2$, $-\text{NH-CO-(C}_1\text{-C}_6\text{ alkyl)}$, for example $-\text{NH-CO-Me}$, $-\text{CO}_2\text{-(C}_1\text{-C}_6\text{ alkyl)}$, for example $-\text{CO}_2\text{Me}$, $-\text{CONH-aryl}$, for example $-\text{CONH-phenyl}$, $-\text{CONHOH}$, $-\text{CON(OH)-(C}_1\text{-C}_6\text{ alkyl)-aryl}$, for example $-\text{CON(OH)-benzyl}$, $-\text{S-(C}_1\text{-C}_6\text{ alkyl)-aryl}$, for example $-\text{S-CH}_2\text{-phenyl}$, $-\text{S-(C}_1\text{-C}_6\text{ alkyl)-CO-R}$ wherein R is aryl or $C_1\text{-C}_6$ alkyl, for example $-\text{S-CH}_2\text{-CO-phenyl}$, $-\text{S-CH}_2\text{-CO-Et}$ and $-\text{S-CH}_2\text{-CO-tBu}$ and $-\text{S-(C}_1\text{-C}_6\text{ alkyl)-CO}_2\text{R}$ wherein R is aryl or $C_1\text{-C}_6$ alkyl, for example $-\text{S-CH}_2\text{-CO}_2\text{Et}$. Typically, these particularly preferred substituents are selected from $C_1\text{-C}_6$ alkyl, for example $-\text{CH}_2\text{OH}$, $-\text{CH}_2\text{NH}_2$, $-(\text{CH}_2)_3\text{OMe}$, $-\text{CH}_2\text{NMe}_2$ and methyl, halogen, $-\text{SH}$, hydroxy, aryl, for example phenyl, $C_1\text{-C}_6$ alkoxy, $C_2\text{-C}_6$ alkenyloxy, $C_1\text{-C}_6$ alkylthio, for example methylthio, $C_2\text{-C}_6$ alkenylthio, for example propenylthio, $-\text{CO}_2\text{-(C}_1\text{-C}_6\text{ alkyl)}$, for example $-\text{CO}_2\text{Me}$, $-\text{CONH-aryl}$, for example $-\text{CONH-phenyl}$, $-\text{CONHOH}$, $-\text{CON(OH)-(C}_1\text{-C}_6\text{ alkyl)-aryl}$, for example $-\text{CON(OH)-benzyl}$, $-\text{S-(C}_1\text{-C}_6\text{ alkyl)-aryl}$, for example $-\text{S-CH}_2\text{-phenyl}$ and $-\text{S-(C}_1\text{-C}_6\text{ alkyl)-CO-R}$ wherein R is aryl or $C_1\text{-C}_6$ alkyl, for example $-\text{S-CH}_2\text{-CO-phenyl}$, $-\text{S-CH}_2\text{-CO-Et}$ and $-\text{S-CH}_2\text{-CO-tBu}$.

A heteroaryl group or moiety may optionally be fused to a said aryl group or moiety, to a further heteroaryl group or moiety or to a heterocyclic or carbocyclic group or moiety.

As used herein, a 3- to 6- membered heterocyclic group or moiety is typically a non-aromatic, saturated or unsaturated $C_3\text{-C}_6$ carbocyclic ring in which one or more, for example 1, 2 or 3, of the carbon atoms are replaced by a heteroatom selected from N, O and S. Saturated heterocyclic groups are preferred. Suitable 3- to 6- membered heterocyclic groups include piperidyl, piperazinyl and tetrahydrofuryl groups.

A 3- to 6- membered heterocyclic group may be unsubstituted or substituted at any position. Typically, it is unsubstituted or carries 1, 2 or 3 substituents. Suitable substituents include halogen, hydroxyl, $-\text{SH}$, $C_1\text{-C}_6$ alkyl, for example $-\text{CF}_3$

-12-

and $-\text{CCl}_3$, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, aryl, heteroaryl, 3- to 6- membered heterocyclyl, $\text{C}_3\text{-C}_6$ carbocyclyl, nitro, cyano, $\text{C}_1\text{-C}_6$ alkoxy, $\text{C}_2\text{-C}_6$ alkenyloxy, $\text{C}_2\text{-C}_6$ alkynyloxy, $\text{C}_1\text{-C}_6$ alkylthio, $\text{C}_2\text{-C}_6$ alkenylthio, $\text{C}_2\text{-C}_6$ alkynylthio, $-\text{OR}$, $-\text{SR}$, $-\text{COR}'$, $-\text{CO}_2\text{R}''$, $-\text{CONR}'''\text{R}''''$ and $-\text{NR}'''\text{R}''''$ wherein R is aryl, heteroaryl or $-\text{XY}$ wherein X is a divalent $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl or $\text{C}_2\text{-C}_6$ alkynyl group and Y is an aryl or heteroaryl group, R' is selected from R, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl and $\text{C}_2\text{-C}_6$ alkynyl, R'' is selected from R' and hydrogen and R''' and R'''' are the same or different and are selected from R', hydrogen and hydroxy. Further suitable substituents include $-\text{S-X-COR}$ and $-\text{O-X-COR}$, wherein X is a divalent $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl or $\text{C}_2\text{-C}_6$ alkynyl group and R is aryl or heteroaryl.

Preferred substituents include halogen, for example chlorine, fluorine and bromine, $-\text{SH}$, hydroxy, $\text{C}_1\text{-C}_6$ alkyl, for example t-butyl, methyl, $-\text{CF}_3$, $-\text{CCl}_3$, $-\text{CH}_2\text{OH}$, $-\text{CH}_2\text{NMe}_2$, $-\text{CH}_2\text{NH}_2$ and $-(\text{CH}_2)_3\text{OMe}$, aryl, heteroaryl, 3- to 6- membered heterocyclyl, $\text{C}_3\text{-C}_6$ carbocyclyl, nitro, cyano, $\text{C}_1\text{-C}_6$ alkoxy, $\text{C}_2\text{-C}_6$ alkenyloxy, $\text{C}_1\text{-C}_6$ alkylthio, $\text{C}_2\text{-C}_6$ alkenylthio, $-\text{OR}$, $-\text{SR}$, $-\text{COR}'$, $-\text{CO}_2\text{R}''$, $-\text{CONR}'''\text{R}''''$ and $-\text{NR}'''\text{R}''''$ wherein R is aryl or $-(\text{C}_1\text{-C}_6 \text{ alkyl})\text{-aryl}$, R' is selected from R or $\text{C}_1\text{-C}_6$ alkyl, R'' is selected from R' and hydrogen and R''' and R'''' are the same or different and are selected from R', hydrogen and hydroxy, and $-\text{S}(\text{C}_1\text{-C}_6 \text{ alkyl})\text{-CO-R}$, wherein R is aryl or $\text{C}_1\text{-C}_6$ alkyl.

More preferred substituents include halogen, for example fluorine, chlorine and bromine, $-\text{SH}$, hydroxy, $\text{C}_1\text{-C}_6$ alkyl, for example, methyl, ethyl, propyl, n-butyl, t-butyl, $-\text{CF}_3$, $-\text{CCl}_3$, $-\text{CH}_2\text{OH}$, $-\text{CH}_2\text{NMe}_2$, $-\text{CH}_2\text{NH}_2$ and $-(\text{CH}_2)_3\text{OMe}$, aryl, for example phenyl, $\text{C}_3\text{-C}_6$ carbocyclyl, for example cyclohexane, $\text{C}_1\text{-C}_6$ alkoxy, $\text{C}_2\text{-C}_6$ alkenyloxy, $\text{C}_1\text{-C}_6$ alkylthio, for example methylthio and ethylthio, $\text{C}_2\text{-C}_6$ alkenylthio, for example ethenylthio and propenylthio, $-\text{CO}_2\text{H}$, $-\text{CO}_2\text{-(C}_1\text{-C}_6 \text{ alkyl)}$, for example $-\text{CO}_2\text{Me}$ and $-\text{CO}_2\text{Et}$, $-\text{CONH-aryl}$, for example $-\text{CONH-phenyl}$, $-\text{CONH-OH}$, $-\text{CONH-(C}_1\text{-C}_6 \text{ alkyl)}$, for example $-\text{CONH}(\text{CH}_2)_2\text{NMe}_2$, $-\text{CON(OH)-(C}_1\text{-C}_6 \text{ alkyl)-aryl}$, for example $-\text{CON(OH)-CH}_2\text{-phenyl}$, $\text{NR}'\text{R}''$ wherein R' and R'' are the same or different and are hydrogen or $\text{C}_1\text{-C}_6$ alkyl, for example NH_2 , NMe_2 and NHEt , $-\text{S}(\text{C}_1\text{-C}_6 \text{ alkyl})\text{-aryl}$ for example $-\text{S-CH}_2\text{-phenyl}$, and $-\text{S}(\text{C}_1\text{-C}_6 \text{ alkyl})\text{-CO-R}$ wherein R is

aryl, for example phenyl, or C₁-C₆ alkyl, for example ethyl or t-butyl.

When a said aryl, heteroaryl, C₃-C₆ carbocyclic or 3- to 6-membered heterocyclic group is substituted by a substituent which includes an aryl, heteroaryl, carbocyclic or heterocyclic moiety, the aryl, heteroaryl, carbocyclic or heterocyclic moiety in the substituent is typically unsubstituted or substituted by one or more further substituent selected from halogen, hydroxy, C₁-C₆ alkyl, for example C₁-C₆ haloalkyl, C₁-C₆ alkoxy, for example C₁-C₆ haloalkoxy and -NR'R'' wherein R' and R'' are the same or different and represent hydrogen or C₁-C₆ alkyl. Typically, these further substituents are themselves unsubstituted.

As used herein, a said alkoxy group is typically a said alkyl group attached to an oxygen atom. A preferred alkoxy group is a haloalkoxy group. A said alkenyloxy group is typically a said alkenyl group attached to an oxygen atom. A said alkynyloxy group is typically a said alkynyl group attached to an oxygen atom. A said alkylthio group is typically a said alkyl group attached to a thio group. A said alkenylthio group is typically a said alkenyl group attached to a thio group. A said alkynylthio group is typically a said alkynyl group attached to a thio group.

A haloalkyl or haloalkoxy group is typically a said alkyl or alkoxy group substituted by one or more said halogen atoms. Typically it is substituted by 1, 2 or 3 said halogen atoms. Preferred haloalkyl and haloalkoxy groups include perhaloalkyl and perhaloalkoxy groups such as -CX₃ and -OCX₃ wherein X is a said halogen atom. Particularly preferred haloalkyl groups are CF₃ and CCl₃. Particularly preferred haloalkoxy groups are -OCF₃ and -OCCl₃.

Preferably R₁ is C₁-C₆ alkyl, aryl or -(C₁-C₆ alkyl)-aryl. More preferably, R₁ is C₁-C₆ alkyl, phenyl or benzyl. Most preferably, R₁ is benzyl. Typically, the group R₁ is unsubstituted or is substituted by one or more, for example 1, 2 or 3, selected from halogen, hydroxyl, C₁-C₆ alkyl, C₁-C₆ alkoxy and -NR'R'' wherein R' and R'' are the same or different and are selected from hydrogen and C₁-C₆ alkyl.

R₂ is preferably aryl, heteroaryl, 3- to 6- membered heterocyclyl, C₃-C₆ carbocyclyl, C₁-C₆ alkyl, C₂-C₆ alkenyl, -CONR'R'' or -CO₂R' wherein each R' and R'' are the same or different and are selected from hydrogen, C₁-C₆ alkyl, aryl and

heteroaryl.

More preferably, R_2 is aryl, for example phenyl, heteroaryl, for example thienyl, furanyl and oxadiazolyl, 3- to 6- membered heterocyclyl, C_1 - C_6 alkyl, for example, methyl, n-butyl, t-butyl and $-(CH_2)_4NH\text{Et}$, or $-\text{CONR}'R''$ wherein R' and R'' are the same or different and are selected from hydrogen, C_1 - C_6 alkyl, aryl and heteroaryl, for example $-\text{CONH}(CH_2)_2NMe_2$, $-\text{CO-NH-phenyl}$ and $-\text{CONH-X}$ wherein X is isoxazolyl or pyridyl. Typically, these more preferred R_2 substituents are selected from aryl, for example phenyl, heteroaryl, for example furanyl and oxadiazolyl, 3- to 6- membered heterocyclyl, C_1 - C_6 alkyl, for example, methyl, n-butyl, t-butyl and $-(CH_2)_4NH\text{Et}$, or $-\text{CONR}'R''$ wherein R' and R'' are the same or different and are selected from hydrogen, C_1 - C_6 alkyl and aryl, for example $-\text{CONH}(CH_2)_2NMe_2$ and $-\text{CO-NH-phenyl}$.

Typically, when R_2 is a heteroaryl group, it is an oxadiazolyl group. Typically, when R_2 is an alkyl group, it is not substituted by a methylamino or dimethylamino group. More typically, when R_2 is an alkyl group it is not substituted by a group of formula $-\text{NR}'R''$ wherein R' and R'' are the same or different and each represent hydrogen or C_1 - C_6 alkyl.

When R_3 and R_4 do not, together with the carbon atoms to which they are attached, form a phenyl group, R_3 is preferably hydrogen. R_4 is preferably C_1 - C_6 alkyl, aryl, heteroaryl, $-\text{CONR}'-\text{NR}''\text{COR}$, $-\text{CONR}'-\text{NR}''\text{CS-R}$, $-\text{CO}_2R'$, $-\text{CONR}'R''$, $-\text{CONR}'-\text{NR}''\text{CO-NR}'''R''''$ or $-\text{CONR}'-\text{NR}''\text{CS-NR}'''R''''$ wherein each R is the same or different and is selected from C_1 - C_6 alkyl, aryl, $-(C_1-C_6 \text{ alkyl})$ -aryl and heteroaryl, and each R' , R'' , R''' and R'''' is the same or different and is selected from hydrogen, C_1 - C_6 alkyl, aryl, $-(C_1-C_6 \text{ alkyl})$ -aryl and heteroaryl. Typically, these preferred R_4 substituents are selected from C_1 - C_6 alkyl, aryl, heteroaryl, $-\text{CONR}'-\text{NR}''\text{COR}$, $-\text{CONR}'-\text{NR}''\text{CS-R}$, CO_2R' , $-\text{CONR}'R''$, $-\text{CONR}'-\text{NR}''\text{CO-NR}'''R''''$ or $-\text{CONR}'-\text{NR}''\text{CS-NR}'''R''''$ wherein each R is the same or different and is selected from C_1 - C_6 alkyl and aryl and each R' , R'' , R''' and R'''' is the same or different and is selected from hydrogen, C_1 - C_6 alkyl and aryl.

More preferably, R_4 is C_1 - C_6 alkyl, for example methyl, heteroaryl, for

-15-

example triazolyl, $-\text{CONR}'-\text{NR}''\text{COR}$, $-\text{CONR}'\text{R}''$, $-\text{CONR}'\text{NR}''\text{CO}-\text{NR}'''\text{R}''''$ or $-\text{CONR}'-\text{NR}''\text{CS}-\text{NR}'''\text{R}''''$ wherein R is C_1-C_6 alkyl or aryl and each R' , R'' , R''' and R'''' is the same or different and is selected from hydrogen, C_1-C_6 alkyl, aryl, $-(\text{C}_1-\text{C}_6 \text{ alkyl})$ -aryl and heteroaryl. Typically, the $-\text{CONR}'-\text{NR}''\text{COR}$ moiety is $-\text{CONH}-$
 5 NHCO -phenyl or $-\text{CONH}-\text{NHCO}-\text{tBu}$. Typically, the $-\text{CONR}'\text{R}''$ moiety is $-\text{CO}-\text{NH}-\text{Z}$ wherein Z is H, phenyl, benzyl, $-\text{ethyl-phenyl}$, pyridyl, thiazolyl or oxadiazolyl. More typically, the moiety $-\text{CONR}'\text{R}''$ is $-\text{CONH-phenyl}$ or $-\text{CONH}_2$. Typically, the $-\text{CONR}'-\text{NR}''\text{CONR}'''\text{R}''''$ moiety is $-\text{CONH}-\text{NHCO}-\text{NH-phenyl}$. Typically, the $-\text{CONR}'-\text{NR}''\text{CS}-\text{NR}'''\text{R}''''$ moiety is $-\text{CONH}-\text{NHCS}-\text{NHMe}$.

- 10 Typically, when R_4 is an alkyl group, it is not substituted by a methylamino or dimethylamino group. More typically, when R_4 is an alkyl group, it is not substituted by a group of formula $-\text{NR}'\text{R}''$ wherein R' and R'' are the same or different and each represent hydrogen or C_1-C_6 alkyl.

Preferred compounds of the invention are compounds of formula (I), as
 15 defined above, and pharmaceutically acceptable salts thereof, wherein:

- R_1 is C_1-C_6 alkyl, aryl or $-(\text{C}_1-\text{C}_6 \text{ alkyl})$ -aryl;
- R_2 is aryl, heteroaryl, 3- to 6- membered heterocyclyl, C_3-C_6 carbocyclyl, C_1-C_6 alkyl, C_2-C_6 alkenyl, $-\text{CONR}'\text{R}''$ or $-\text{CO}_2\text{R}'$ wherein each R' and R'' are the same or different and are selected from hydrogen, C_1-C_6 alkyl, aryl and
 20 heteroaryl; and
- either R_3 and R_4 , together with the carbon atoms to which they are attached, form a phenyl group or R_3 is hydrogen and R_4 is C_1-C_6 alkyl, aryl, heteroaryl, $-\text{CONR}'-\text{NR}''\text{COR}$, $-\text{CONR}'-\text{NR}''\text{CS}-\text{R}$, $-\text{CO}_2\text{R}'$, $-\text{CONR}'\text{R}''$, $-\text{CONR}'-\text{NR}''\text{CO}-\text{NR}'''\text{R}''''$ or $-\text{CONR}'-\text{NR}''\text{CS}-\text{NR}'''\text{R}''''$ wherein each R is the same or different
 25 and is selected from C_1-C_6 alkyl, aryl, $-(\text{C}_1-\text{C}_6 \text{ alkyl})$ -aryl and heteroaryl and each R' , R'' , R''' and R'''' is the same or different and is selected from hydrogen, C_1-C_6 alkyl, aryl, $-(\text{C}_1-\text{C}_6 \text{ alkyl})$ -aryl and heteroaryl.

Further preferred compounds of the invention are compounds of formula (I), as defined above, and pharmaceutically acceptable salts thereof, wherein:

- 30 - R_1 is C_1-C_6 alkyl, phenyl or benzyl;


-16-

- 5 - R_2 is aryl, for example phenyl, heteroaryl, for example thienyl, furanyl and oxadiazolyl, 3- to 6- membered heterocyclyl, C_1 - C_6 alkyl, for example, methyl, n-butyl, t-butyl and $-(CH_2)_4NH\text{Et}$, or $-\text{CONR}'R''$ wherein R' and R'' are the same or different and are selected from hydrogen, C_1 - C_6 alkyl, aryl and heteroaryl, for example $-\text{CONH}(CH_2)_2NMe_2$, $-\text{CO-NH-phenyl}$ and $-\text{CONH-X}$ wherein X is isoxazolyl or pyridyl; and
- 10 - either R_3 and R_4 , together with the carbon atoms to which they are attached, form a phenyl group, or R_3 is hydrogen and R_4 is C_1 - C_6 alkyl, for example methyl, heteroaryl, for example triazolyl, $-\text{CONR}'-\text{NR}''\text{COR}$, $-\text{CONR}'R''$, $-\text{CONR}'\text{NR}''\text{CO-NR}'''R''''$ or $-\text{CONR}'-\text{NR}''\text{CS-NR}'''R''''$ wherein R is C_1 - C_6 alkyl or aryl and each R' , R'' , R''' and R'''' is the same or different and is selected from hydrogen, C_1 - C_6 alkyl, aryl, $-(C_1-C_6 \text{ alkyl})$ -aryl and heteroaryl.

In a further preferred embodiment of the invention, R_3 and R_4 , together with the carbon atoms to which they are attached, form a phenyl group. This phenyl

15 group may be unsubstituted or substituted at any position. Typically, it is unsubstituted or carries 1, 2 or 3 substituents. Suitable substituents include those mentioned above as appropriate substituents for an aryl group. Preferred substituents include C_1 - C_6 alkyl, for example methyl, ethyl $-\text{CF}_3$ and $-\text{CCl}_3$, halogen, for example chlorine, hydroxy, C_1 - C_6 alkoxy, for example methoxy and ethoxy, and

20 $-\text{NR}'R''$ wherein R' and R'' are the same or different and are selected from hydrogen and C_1 - C_6 alkyl. Thus, preferred indazole compounds of the invention have the formula (Ia) as set out below.




wherein R_1 and R_2 are as defined above and Z denotes one or more,

30 preferably one or two, selected from hydrogen, C_1 - C_6 alkyl, for example methyl,

-17-

ethyl, $-\text{CF}_3$ and $-\text{CCl}_3$, halogen, for example chlorine, hydroxy, $\text{C}_1\text{-C}_6$ alkoxy, for example methoxy or ethoxy, and $-\text{NR}'\text{R}''$ wherein R' and R'' are the same or different and are selected from hydrogen and $\text{C}_1\text{-C}_6$ alkyl.

In a further preferred embodiment of the invention, R_4 is a thiosubstituted triazole group. Such compounds have the formula (Ib) and, together with their pharmaceutically acceptable salts, constitute preferred compounds of the invention



wherein:

- R_1 and R_2 are as defined above;
- A is hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl, aryl, heteroaryl, 3- to 6-membered heterocyclyl or $\text{C}_3\text{-C}_6$ carbocyclyl; and
- B is hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, aryl, heteroaryl, $-\text{XY}$ wherein X is a divalent $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl or $\text{C}_2\text{-C}_6$ alkynyl group and Y is an aryl or heteroaryl group, or $-\text{X}'\text{-COR}$ or $-\text{X}'\text{-CO}_2\text{R}$ wherein X' is a divalent $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl or $\text{C}_2\text{-C}_6$ alkynyl group and R is $\text{C}_1\text{-C}_6$ alkyl, aryl or heteroaryl.

Typically, in the formula (Ib), A is aryl, for example phenyl, $\text{C}_3\text{-C}_6$ carbocyclyl, for example cyclohexyl, or $\text{C}_1\text{-C}_6$ alkyl, for example methyl. Typically, B is hydrogen, $\text{C}_1\text{-C}_6$ alkyl, for example methyl and ethyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, for example propynyl, aryl, for example phenyl, $-(\text{C}_1\text{-C}_6 \text{ alkyl})\text{-aryl}$, for example benzyl, $-(\text{C}_1\text{-C}_6 \text{ alkyl})\text{-CO}_2\text{R}$ or $-(\text{C}_1\text{-C}_6 \text{ alkyl})\text{-COR}$ wherein R is $\text{C}_1\text{-C}_6$ alkyl, for example ethyl and t-butyl, or aryl, for example phenyl.

Preferred compounds of formula (Ib) are compounds in which:

- R_1 is $\text{C}_1\text{-C}_6$ alkyl or $-(\text{C}_1\text{-C}_6 \text{ alkyl})\text{-aryl}$, for example benzyl;
- R_2 is hydrogen or $\text{C}_1\text{-C}_6$ alkyl;
- A is aryl, for example phenyl, $\text{C}_3\text{-C}_6$ carbocyclyl, for example


-18-

cyclohexyl, or C_1 - C_6 alkyl, for example methyl; and

- B is hydrogen, C_1 - C_6 alkyl, for example methyl and ethyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, for example propynyl, aryl, for example phenyl, $-(C_1$ - C_6 alkyl)-aryl, for example benzyl, $-(C_1$ - C_6 alkyl)- CO_2R or $-(C_1$ - C_6 alkyl)-COR wherein R is C_1 - C_6 alkyl, for example ethyl and t-butyl, or aryl, for example phenyl;

and pharmaceutically acceptable salts thereof.

In a further preferred embodiment of the invention, R_2 is a carboxamide group. Such compounds have the formula (Ic) and, together with their pharmaceutically acceptable salts, constitute preferred compounds of the invention.



wherein:

- R_1 and R_4 are as defined above; and
- C is aryl, heteroaryl, 3- to 6-membered heterocyclyl or C_3 - C_6 carbocyclyl.

Preferably, C in the formula (Ic) is an aryl or heteroaryl group optionally substituted with 1 or 2 of the substituents mentioned above as suitable for an aryl or heteroaryl group.

Preferred compounds of formula (Ic) are compounds in which


- R_1 is aryl, for example phenyl, $-(C_1$ - C_6 -alkyl)-aryl, for example benzyl, or C_1 - C_6 alkyl;
- R_4 is aryl, for example phenyl, or C_1 - C_6 alkyl; and
- C is aryl or heteroaryl

and pharmaceutically acceptable salts thereof.

In a further preferred embodiment of the invention, R_4 is a carboxamide group. Such compounds have the formula (Id) and, together with their

-19-

pharmaceutically acceptable salts, constitute preferred compounds of the invention



wherein:

- R₁ and R₂ are as defined above; and
- D is aryl, heteroaryl, 3- to 6-membered heterocyclyl, C₃-C₆ carbocyclyl, -XY wherein X is a divalent C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl group and Y is aryl, heteroaryl, 3- to 6-membered heterocyclyl or C₃-C₆ carbocyclyl, or -NR''CO-NR'''R'''' wherein R'' and R''' are the same or different and are hydrogen or C₁-C₆ alkyl and R'''' is hydrogen, C₁-C₆ alkyl or aryl, for example phenyl.

15 Preferably, D in the formula (Id) is an aryl, heteroaryl or -(C₁-C₆ alkyl)-aryl group optionally substituted by 1 or 2 of the substituents mentioned above as suitable for an aryl or heteroaryl group, or is -NH-CO-NH-aryl, for example -NH-CO-NH-(3-chlorophenyl).

Preferred compounds of formula (Id) are compounds in which

- 20 - R₁ is C₁-C₆ alkyl, aryl, for example phenyl, or -(C₁-C₆ alkyl)-aryl, for example benzyl;
- R₂ is C₁-C₆ alkyl, aryl, for example phenyl, or heteroaryl, for example thienyl; and
- D is aryl, for example phenyl, heteroaryl, for example pyridyl, thiazolyl and oxadiazolyl or -(C₁-C₆ alkyl)-aryl, for example benzyl

25 and -ethyl-phenyl

and pharmaceutically acceptable salts thereof.

For the avoidance of doubt, any of the moieties present in the substituents of the preferred compounds of formulae (Ia), (Ib), (Ic) and (Id) may be unsubstituted or

30 substituted by one or more of the substituents discussed above as suitable for the

-20-

moiety in question.

Typically, in the compounds of the invention, when R₁ is benzyl and R₃ and R₄, together with the carbon atoms to which they are attached, form a phenyl group, R₂ is not furanyl or phenyl. More typically, R₂ is not furanyl, phenyl, pyrrolyl, or
 5 thienyl. In other words, the compounds of the invention are typically not 1-benzyl-3-(furanyl, phenyl, pyrrolyl or thienyl)-indazoles. Preferably, the compounds of the invention which are indazoles do not carry an aryl or heteroaryl group at the 3-position. In other words, the compounds of the invention are preferably not 1-benzyl-3-aryl-indazoles or 1-benzyl-3-heteroaryl-indazoles.

10 The present invention includes pharmaceutically acceptable salts of the compounds of the invention. Suitable salts include salts with pharmaceutically acceptable acids, both inorganic acids such as hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic or nitric acid and organic acids such as citric, fumaric, maleic, malic, ascorbic, succinic, tartaric, benzoic, acetic, methanesulphonic,
 15 ethanesulphonic, benzenesulphonic or p-toluenesulphonic acid. Salts may also be formed with pharmaceutically acceptable bases such as alkali metal (eg sodium or potassium) and alkali earth metal (eg calcium or magnesium) hydroxides and organic bases such as alkyl amines, aralkyl amines or heterocyclic amines.

Particularly preferred compounds of the invention are:

20 1-Benzyl-3-(5-hydroxymethyl-2-furyl)-1H-indazole
 1-Benzyl-3-(5-methoxycarbonyl-2-furyl)-1H-indazole
 1-Benzyl-3-[3-aminomethyl-1,2,4-oxadiazol-5-yl]indazole
 1-Benzyl-3-(5-hydroxylaminocarbonyl-2-furyl)-1H indazole
 1-Benzyl-3-[3-(N,N-dimethylaminomethyl)-1,2,4-oxadiazol-5-yl]indazole
 25 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid N'-(3-chlorophenylcarbonyl) hydrazide
 2-{5-[5-tert-Butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl}-1-(4-chloro-phenyl)-ethanone
 3-Benzylsulfanyl-5-[5-tert-butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-
 30 methyl-4H-[1,2,4]triazole

- 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid (4-chloro-phenyl)-amide
[N-Ethyl-(4-aminobutyl)]-1-benzylindazole
- 1-Benzyl-3-[N-(2-N,N-dimethylaminoethyl)carboxamido]indazole
- 5-(1-Benzyl-1H-indazol-3-yl)-furan-2-carboxylic acid benzyl-hydroxy-amide
- 5 5-(1-Benzyl-1H-indazol-3-yl)-furan-2-carboxylic acid N-benzylhydroxyl
amine ester
- 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid (4-chloro-phenyl)-amide
- 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid (2-chloro-phenyl)-amide
- 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid p-tolylamide
- 10 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid (4-bromo-3-chloro-
phenyl)-amide
- 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid N'-[1-(4-chloro-phenyl)-
methanoyl]-hydrazide
- 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid N'-
- 15 (phenylcarbamoyl)hydrazide
- 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid N'-(3-
chlorobenzoyl)hydrazide
- 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid amide
- 1-tert-Butyl-5-methyl-1H-pyrazole-3-carboxylic acid (4-chloro-phenyl)-
- 20 amide
- 1-tert-Butyl-5-methyl-1H-pyrazole-3-carboxylic acid (4-tert-butyl-phenyl)-
amide
- 5-tert-Butyl-2-methyl-2H-pyrazole-3-carboxylic acid phenylamide
- 5-tert-Butyl-2-methyl-2H-pyrazole-3-carboxylic acid (4-chloro-phenyl)-
- 25 amide
- 5-tert-Butyl-2-methyl-2H-pyrazole-3-carboxylic acid (4-tert-butyl-phenyl)-
amide
- 5-Methyl-2-(4-methyl-benzyl)-2H-pyrazole-3-carboxylic acid (4-chloro-
phenyl)-amide
- 30 5-Methyl-2-(4-methyl-benzyl)-2H-pyrazole-3-carboxylic acid (2-chloro-

- phenyl)-amide
- 5-Methyl-2-(4-methyl-benzyl)-2H-pyrazole-3-carboxylic acid (3-trifluoromethyl-phenyl)-amide
- 5-Methyl-2-(4-methyl-benzyl)-2H-pyrazole-3-carboxylic acid p-tolylamide
- 5-Methyl-2-(3-trifluoromethyl-benzyl)-2H-pyrazole-3-carboxylic acid (2,4-dichloro-phenyl)-amide
- 5-Methyl-2-(3-trifluoromethyl-benzyl)-2H-pyrazole-3-carboxylic acid (4-cyclohexyl-phenyl)-amide
- 5-Methyl-1-(4-methyl-benzyl)-1H-pyrazole-3-carboxylic acid (4-bromo-phenyl)-amide
- 5-Methyl-1-(4-methyl-benzyl)-1H-pyrazole-3-carboxylic acid phenylamide
- 1-(2,6-Dichloro-benzyl)-5-methyl-1H-pyrazole-3-carboxylic acid (3-methyl-phenyl)-amide
- 1-(2,6-Dichloro-benzyl)-5-methyl-1H-pyrazole-3-carboxylic acid (4-tert-butyl-phenyl)-amide
- 2-[5-(2-Ethyl-5-methyl-2H-pyrazol-3-yl)-4-phenyl-4H-[1,2,4]triazol-3-ylsulfanyl]-1-phenyl-ethanone
- 2-[4-(4-Chloro-phenyl)-5-(2-ethyl-5-methyl-2H-pyrazol-3-yl)-4H-[1,2,4]triazol-3-ylsulfanyl]-1-phenyl-ethanone
- 2-[5-(2-Ethyl-5-methyl-2H-pyrazol-3-yl)-4-(3-methoxy-propyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-1-phenyl-ethanone
- 2-[5-(2-Ethyl-5-methyl-2H-pyrazol-3-yl)-4-(3-trifluoromethyl-phenyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-1-phenyl-ethanone
- 5-[5-tert-Butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-methyl-4H-[1,2,4]triazole-3-thiol
- 3-[5-tert-Butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-methyl-5-methylsulfanyl-4H-[1,2,4]triazole
- 3-Allylsulfanyl-5-[5-tert-butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-methyl-4H-[1,2,4]triazole
- 3-Benzylsulfanyl-5-[5-tert-butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-

-23-

- methyl-4H-[1,2,4]triazole
- 2-{5-[5-tert-Butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl}-1-phenyl-ethanone
- 2-{5-[5-tert-Butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl}-1-(4-chloro-phenyl)-ethanone
- 5 {5-[5-tert-Butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl}-acetic acid ethyl ester
- 1-{5-[5-tert-Butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl}-3,3-dimethyl-butan-2-one
- 10 2-Ethyl-5-methyl-2H-pyrazole-3-carboxylic acid N'-[1-(3-chloro-phenyl)-methanoyl]-hydrazide
- Benzoic acid N'-[1-(2-benzyl-5-tert-butyl-2H-pyrazol-3-yl)-methanoyl]-hydrazide
- 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid N'-[1-(4-trifluoromethyl-phenyl)-methanoyl]-hydrazide
- 15 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid N'-(2,2-dimethylpropanoyl)-hydrazide
- 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid N'-(2,6-dimethylphenylcarbamoyl)hydrazide
- 20 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid N'-(3-trifluoromethylphenylcarbamoyl)hydrazide
- 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid N'-(methylthiocarbamoyl)hydrazide
- 25 3-(Benzylthio)-5-(1-ethyl-3-methyl-1H-pyrazol-5-yl)-4-phenyl-4H-1,2,4-triazolehemihydrate
- 5-[3-(tert-Butyl)-1-(3-methylbenzyl)pyrazol-5-yl]-4-cyclohexyl-1,2,4-triazole-3-thiol
- 5-[3-tert-Butyl-1-(2,4-dichlorobenzyl)pyrazol-5-yl]-4-methyltriazole-3-thiol
- Ethyl 2-([5-[3-(tert-butyl)-1-(3-methylbenzyl)-1H-pyrazol-5-yl]-4-cyclohexyl-4H-1,2,4-triazol-3-yl]thio)acetate
- 30

-24-

- 3-[3-(*tert*-Butyl)-1-(2,4-dichlorobenzyl)-1*H*-pyrazol-5-yl]-4-phenyl-5-(prop-2-ynylthio)-4*H*-1,2,4-triazole
- 2-Benzyl-5-*tert*-butyl-2*H*-pyrazole-3-carboxylic acid phenylamide
- 2-Benzyl-5-*tert*-butyl-2*H*-pyrazole-3-carboxylic acid benzylamide
- 5 1-(4-Chloro-phenyl)-5-phenyl-1*H*-pyrazole-3-carboxylic acid phenylamide
- 5-*tert*-Butyl-2-(2,4-dichloro-benzyl)-2*H*-pyrazole-3-carboxylic acid (4-methoxy-phenyl)-amide
- 2-Ethyl-5-thiophen-2-yl-2*H*-pyrazole-3-carboxylic acid (4-chloro-phenyl)-amide
- 10 (S)-5-*tert*-Butyl-2-(2,4-dichloro-benzyl)-2*H*-pyrazole-3-carboxylic acid (4-chloro-phenyl)-amide
- 5-*tert*-Butyl-2-(2,4-dichloro-benzyl)-2*H*-pyrazole-3-carboxylic acid phenethyl-amide
- (S)-2-Ethyl-5-thiophen-2-yl-2*H*-pyrazole-3-carboxylic acid phenethyl-amide
- 15 5-*tert*-Butyl-2-(2,4-dichloro-benzyl)-2*H*-pyrazole-3-carboxylic acid phenylamide
- 5-*tert*-Butyl-2-(2,4-dichloro-benzyl)-2*H*-pyrazole-3-carboxylic acid benzylamide
- 1-(4-Chloro-phenyl)-5-phenyl-1*H*-pyrazole-3-carboxylic acid (4-dimethylamino-phenyl)-amide
- 20 1-(4-Chloro-phenyl)-5-phenyl-1*H*-pyrazole-3-carboxylic acid (4-*tert*-butyl-phenyl)-amide
- 2-*tert*-Butyl-5-methyl-2*H*-pyrazole-3-carboxylic acid (4-*tert*-butyl-phenyl)-amide
- 25 2-*tert*-Butyl-5-methyl-2*H*-pyrazole-3-carboxylic acid (3,4-dichloro-phenyl)-amide
- 5-*tert*-Butyl-2-methyl-2*H*-pyrazole-3-carboxylic acid (3,4-dichloro-phenyl)-amide
- 2-Benzyl-5-*tert*-butyl-2*H*-pyrazole-3-carboxylic acid (3,4-dichloro-phenyl)-amide
- 30

-25-

- 2-Benzyl-5-*tert*-butyl-2*H*-pyrazole-3-carboxylic acid (4-*tert*-butyl-phenyl)-amide
- 5-*tert*-Butyl-2-methyl-2*H*-pyrazole-3-carboxylic acid (4-*tert*-butyl-phenyl)-amide
- 5 2-Benzyl-5-*tert*-butyl-2*H*-pyrazole-3-carboxylic acid (4-dimethylamino-phenyl)-amide
- 2-Benzyl-5-*tert*-butyl-2*H*-pyrazole-3-carboxylic acid (3-oxazol-5-yl-phenyl)-amide
- 5-*tert*-Butyl-2-methyl-2*H*-pyrazole-3-carboxylic acid (3-oxazol-5-yl-phenyl)-amide
- 10 1-(4-Chloro-phenyl)-5-phenyl-1*H*-pyrazole-3-carboxylic acid (5-*tert*-butyl-isoxazol-3-yl)-amide
- 2-*tert*-Butyl-5-methyl-2*H*-pyrazole-3-carboxylic acid (4-phenylcarbamoyl-phenyl)-amide
- 15 2-Benzyl-5-*tert*-butyl-2*H*-pyrazole-3-carboxylic acid (3-phenylcarbamoyl-phenyl)-amide
- 5-*tert*-Butyl-2-methyl-2*H*-pyrazole-3-carboxylic acid (3-phenylcarbamoyl-phenyl)-amide
- 2-Benzyl-5-*tert*-butyl-2*H*-pyrazole-3-carboxylic acid (6-chloro-pyridin-3-yl)-amide
- 20 1-*tert*-Butyl-5-methyl-1*H*-pyrazole-3-carboxylic acid (6-chloro-pyridin-3-yl)-amide
- 1-*tert*-Butyl-5-methyl-1*H*-pyrazole-3-carboxylic acid (4-acetylamino-phenyl)-amide
- 25 1-*tert*-Butyl-5-methyl-1*H*-pyrazole-3-carboxylic acid (3-benzyloxy-pyridin-2-yl)-amide
- 5-Methyl-1-(4-methyl-benzyl)-1*H*-pyrazole-3-carboxylic acid (4-acetylamino-phenyl)-amide
- 5-*tert*-Butyl-2-(2,4-dichloro-benzyl)-2*H*-pyrazole-3-carboxylic acid (4-acetylamino-phenyl)-amide
- 30

-26-

2-Ethyl-5-thiophen-2-yl-2*H*-pyrazole-3-carboxylic acid (4-acetylamino-phenyl)-amide

5-*tert*-Butyl-2-(2,4-dichloro-benzyl)-2*H*-pyrazole-3-carboxylic acid (4-(pyridin-3-yl) thiazol-2-yl)-amide

5 2-Ethyl-5-thiophen-2-yl-2*H*-pyrazole-3-carboxylic acid (4-(pyridin-3-yl) thiazol-2-yl)-amide

2-Benzyl-5-*tert*-butyl-2*H*-pyrazole-3-carboxylic acid (4-acetylamino-phenyl)-amide

10 5-*tert*-Butyl-2-methyl-2*H*-pyrazole-3-carboxylic acid (4-(pyridin-3-yl) thiazol-2-yl)-amide


5-*tert*-Butyl-2-methyl-2*H*-pyrazole-3-carboxylic acid [3-(4-methoxy-benzyl)-[1,2,4]oxadiazol-5-yl]-amide

and pharmaceutically acceptable salts thereof.

The compounds of formula (I) in which R₄ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-
15 C₆ alkynyl, aryl, heteroaryl or 3- to 6- membered heterocyclyl may be prepared by the process shown in Scheme 1 below. These reactions are described in Grandberg I, *et al.* Zhur. Obshchei Khim. 30, 2920-5 (1960) (CA61, 16517f) and Terent'ev, I, Ibid 30, 2925-31 (CA61, 16518c).

20

-27-

Scheme 1

In Scheme 1, an aldehyde of formula (1), wherein R_4 is $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, aryl, heteroaryl or 3- to 6- membered heterocyclyl, can be reacted with a ketone of formula (2), in which R_2 and R_3 are as defined in the formula


- 5 (I). This condensation is typically conducted in the presence of a base. Suitable bases include sodium hydride, potassium tert butoxide, sodium ethoxide and lithium diisopropylamide. A preferred base is sodium methoxide. The reaction typically takes place at from 0 to 5°C . A compound of formula (3) is thereby prepared.

- The compound of formula (3) can be reacted with a hydrazine of formula (4),
 10 wherein R_1 is as defined in the formula (I), to give a pyrazole of formula (5). This reaction may be carried out in a solvent such as methanol at reflux for from 1 to 4 hours.


The compounds of the formulae (1), (2) and (4) are known compounds or may be prepared by analogy with known methods.

- 15 Compounds in which R_4 is hydrogen can be prepared by analogy with known methods for preparing pyrazoles. For example, a compound of formula (6).

-28-



- 5 wherein R_2 is as defined above, can be reacted with hydrazine to give a compound of formula (I) in which R_1 , R_3 and R_4 are hydrogen. Alternatively, a compound of formula (6a)



10

wherein R_2 and R_3 are as defined in the formula (I), can be reacted with hydrazine to give a compound of formula (I) in which R_1 and R_4 are hydrogen.

- Compounds of formula (I) in which R_1 is hydrogen can be converted to
 15 corresponding compounds of formula (I) in which R_1 is $\text{C}_1\text{-C}_6$ alkyl or $-(\text{C}_1\text{-C}_6 \text{ alkyl})$ -aryl by alkylation with a compound of formula $\text{R}_1\text{-L}$ in which R_1 is $\text{C}_1\text{-C}_6$ alkyl or $-(\text{C}_1\text{-C}_6 \text{ alkyl})$ -aryl and L is a leaving group such as bromine. Typically, the reaction takes place in the presence of a base such as sodium hydride.

- Compounds of formula (I) in which R_1 is hydrogen can be converted to
 20 corresponding compounds of formula (I) in which R_1 is aryl by boronic acid coupling, i.e. by reaction with Ar-B(OH)_2 in the presence of copper acetate. The reaction can be conducted under standard conditions known to those of skill in the art.

- The compounds of formula (I) in which R_4 is $-\text{CONR}'\text{-NR}''\text{COR}$,
 25 $-\text{CONR}'\text{-NR}''\text{CS-R}$, $-\text{CO}_2\text{R}'$, $-\text{CONR}'\text{-NR}''\text{-CO}_2\text{R}'$, $-\text{CONR}'\text{-NR}''\text{-CS-OR}'$, $-\text{CONR}'\text{R}''$, $-\text{CONR}'\text{-NR}''\text{CO-NR}'''\text{R}''''$ and $-\text{CONR}'\text{-NR}''\text{CS-NR}'''\text{R}''''$, wherein R , R' , R'' , R''' and R'''' are as defined above, can be prepared by preparing a compound of formula (5) in which R_4 is 2-furyl according to Scheme 1 above, and oxidising the thus obtained compound of formula (5) to give a compound of formula (I) in which R_4 is $-\text{CO}_2\text{H}$.
 30 This oxidation can be effected using a strong oxidising agent such as potassium

-29-

permanganate. For example, the 2-furyl compounds can be stirred with KMnO_4 in acetone / benzene at from 18 to 20°C for from 1 to 4 hours, then stirred at room temperature for from 1 to 3 days, to give the corresponding carboxylic acids.

The thus obtained carboxylic acids can be esterified with alcohols of formula
 5 HOR, wherein R is as defined above, by known methods, or may be condensed with compounds of formulae $\text{HNR}'\text{R}''$, $\text{HNR}'\text{-NR}''\text{COR}$, $\text{HNR}'\text{-NR}''\text{CS-R}$, $\text{HNR}'\text{-NR}''\text{-CO}_2\text{R}'$, $\text{HNR}'\text{-NR}''\text{CO-NR}'''\text{R}''''$, $\text{HNR}'\text{-NR}''\text{-CS-OR}'$ or $\text{HNR}'\text{-NR}''\text{-CS-NR}'''\text{R}''''$, wherein R, R', R'', R''' and R'''' are as defined above, to give compounds of formula (I) wherein R_4 is as defined above.

10 The condensation or esterification may be effected, for example, by converting the carboxylic acid to an activated derivative such as an acid chloride, for example using PCl_5 or thionyl chloride, or by the use of a coupling agent such as dicyclohexylcarbodiimide or its water soluble derivatives such as 3-(3-dimethylaminopropyl)-1-ethylcarbodiimide. Alternatively, coupling agents such as
 15 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate (HBTU) or O-(7-azabenzotriazol-1-yl)-N,N',N'-tetramethyluroniumhexafluorophosphate (HATU) may be used.

Compounds of formula (I) in which R_4 is -COR can be prepared from corresponding compounds in which R_4 is $-\text{CO}_2\text{H}$ by standard functional group
 20 interconversions known to those of skill in the art. For example, the carboxylic acid can be converted to a corresponding acyl chloride, for example by reaction with PCl_5 or thionyl chloride. The acyl chloride can then be reacted with HMeNOMe, to give Weinreb's amide, which can be reacted with an appropriate nucleophile, for example a Grignard reagent or alkyl or aryl lithium compound to give a compound of formula
 25 (I) in which R_4 is -COR.


Certain compounds of formula (I) in which R_4 is heteroaryl may be conveniently synthesised by the cyclisation of corresponding compounds of formula (I) in which R_4 is a thiosemicarbazide moiety. Such cyclisations may be effected by standard methods known to those of skill in the art.

30 For example, cyclisation of the compounds of formula (I) in which R_4 is

-30-

thiosemicarbazide to corresponding compounds of formula (I) in which R_4 is a thiol substituted 1,2,4 triazole group may be effected by reaction with a base such as sodium hydroxide or potassium *tert* butoxide according to methods described in Czollner L. Arch Pharm. 1990, 323, 221. Alkylation or arylation of the thiol group
 5 may be effected by standard techniques, for example with reagents such as benzyl or phenacyl halides in the presence of a base such as triethylamine or sodium carbonate. Further substituted triazoles can be thereby obtained.

Compounds of the formula (I) wherein R_3 and R_4 together form a phenyl moiety and R_2 is aryl or heteroaryl can be prepared according to Scheme 2 set out
 10 below.

Scheme 2

In Scheme 2 above, a Friedel Crafts acylation of a compound of formula (8) may be effected using, for example, a catalyst such as iron (III) chloride. Other
 30 catalysts such as titanium tetrachloride, tin (IV) chloride or aluminium chloride may

-31-


be employed but iron (III) chloride is preferred. Solvents such as dichloromethane, or 1,2-dichloroethane may be used.

A compound of formula (9) may be reduced to a corresponding compound of formula (10) using, for example, iron metal in acetic acid. Tin (II) chloride may also
5 be used. The conversion of a compound of formula (10) to a corresponding compound of formula (11) can be effected by diazotisation using, for example, sodium nitrite and an acid such as hydrochloric acid or sulfuric acid at -5 to 0°C, followed by reduction of the diazo group with tin (II) chloride and resultant cyclisation.

10 The compounds of formulae (7) and (8) are known compounds, or may be prepared by analogy with known methods.

The Friedel-Crafts reaction between the compounds of formulae (7) and (8) is particularly effective when R_2 is aryl, furyl or thiophenyl.

Compounds of the formula (11) wherein R_2 is 3- to 6- membered
15 heterocyclyl, C_3 - C_6 carbocyclyl, -XR wherein X and R are as defined in the formula (I), C_1 - C_6 alkyl, C_2 - C_6 alkenyl or C_2 - C_6 alkynyl can be prepared by activating a compound of formula (12)



wherein A is a protected amino group, and reacting it with an appropriate nucleophile, followed by cyclisation to form the indazole moiety.

25 The compounds of formula (12) are known compounds or may be prepared by analogy with known methods. They can be activated, for example, by reacting the compound of formula (12) with PCl_5 , to give an acyl chloride, or with triflic anhydride. The activated compound can then be reacted with an appropriate nucleophile to add the R_2 group. Appropriate nucleophiles include Grignard reagents
30 such as R_2 -MgBr and lithium compounds such as R_2 -Li. When R_2 is a heterocyclyl


-32-

group an appropriate nucleophile may be R_2-H .

Following reaction with a nucleophile, the amino group can be deprotected. Subsequent cyclisation leads to a compound of formula (11) wherein R_2 is 3- to 6-membered heterocyclyl, C_3-C_6 carbocyclyl, $-XR$ wherein X and R are as defined in the formula (I), C_1-C_6 alkyl, C_2-C_6 alkenyl or C_2-C_6 alkynyl.

The compounds of formulae (11) and (12) may be alkylated or arylated at the 1- position by reaction with a compound of formula R_1-L or $Ar-B(OH)_2$ as described above.

Compounds of formula (I) in which R_3 and R_4 together form a phenyl group may also be prepared from compounds of formula (13)




15

wherein R_1 is as defined in the formula (I). Such compounds are known, or may be prepared by analogy with known methods. For example, the synthesis of 3-iodo-1H-indazole is taught in Auwers *et al.* J. Prakt. Chem. 1924, 108, 314. 3-Iodo-1H-indazole may be alkylated or arylated at the 1- position by reaction with a compound of formula R_1-L or $ArB(OH)_2$, as described above, to give a compound of formula (13).

20

Compounds of formula (13) can then be reacted with a compound of formula (14)



25

wherein R_2 is aryl, heteroaryl, $-XR$ wherein X is a divalent C_2-C_6 alkenyl or C_2-C_6 alkynyl group and R is as defined above, or R_2 is C_2-C_6 alkenyl or C_2-C_6 alkynyl. Typically, the reaction takes place in the presence of a palladium catalyst such as


30

palladium *tetrakis*-triphenylphosphine.

The compounds of formula (14) are known compounds or may be prepared by analogy with known methods. For example, methyl 2-trimethylstannyl-5-furanoate can be prepared by reaction of methyl 5-bromo-2-furanoate with 5 hexamethylditin in a solvent such as 1,2-dimethoxyethane in the presence of a catalyst such as palladium *tetrakis*-triphenylphosphine.

Compounds of formula (I) where R₂ is a substituted oxadiazole may be conveniently prepared according to Scheme (3) below.

Scheme 3



In Scheme (3), the indazole-3-carboxylic acid of formula (16) can be prepared by methods disclosed in von.Auwers & Dereser, Chem.Ber., 1919, **52**, 1345. The


-34-

compound of formula (16) can be esterified using conc. H_2SO_4 /methanol. Other acids such as hydrochloric acid can also be employed. The compound of formula (17) can be alkylated or arylated by reaction with a compound of formula $\text{R}_1\text{-L}$ or $\text{ArB}(\text{OH})_2$ as set out above, to give a compound of formula (18).

5 Reaction of a compound of formula (18) with a hydroxy amidine in the presence of a base such as sodium hydride can yield the substituted oxadiazoles of formula (19). The substituted hydroxy amidines can be prepared from a nitrile and hydroxylamine in the presence of a base such as sodium methoxide conveniently formed from sodium metal and methanol.

10 Compounds of formula (I) where R_2 is substituted 3-propylamino may conveniently be prepared as shown in Scheme 4 below.

Scheme 4



15 In Scheme 4, the compound of formula (20) can be prepared according to Sasakura *et al.* Synth, Comm, 1988, 18, 159. The chloride can be converted to the

-35-

nitrile of formula (21) using sodium cyanide in DMF at a temperature of 90°. The compound of formula (21) may then be alkylated or arylated with a compound of formula R_1-L or $ArB(OH)_2$ as set out above, to give a compound of formula (22). The compound of formula (22) can then be reduced to a compound of formula (23) using, for example, Raney nickel in ethanol at 65°.

Compounds of formula (I), wherein R_3 and R_4 together form a phenyl group and R_2 is $-COR$, $-CONR'R''$ or $-CO_2R'$ wherein R , R' and R'' are as defined in the formula (I), may be prepared by alkylating or arylating indazole 3-carboxylic acid methyl ester, prepared according to von Auwers & Dereser, Chem. Ber, 1919, 52, 1345 with a compound of formula R_1-L or $ArB(OH)_2$ as described above. The alkylated or arylated compound can then be hydrolysed to the corresponding carboxylic acid using sodium hydroxide. The carboxylic acid can then be esterified or condensed with an amine of formula $HNR'R''$ by known methods, for example in the presence of a coupling agent such as HATU, TBTU or HBTU.

Compounds of formula (I), wherein R_3 and R_4 together form a phenyl group and R_2 is $-COR$ can be prepared from the corresponding carboxylic acids via Weinreb's amide, as described above.

A compound of formula (I) can be salified by known methods, by contacting the compound with an appropriate acid or base.

The compounds of the invention are capable of inhibiting voltage dependent sodium channels. They can therefore be used, for example, to protect cells against damage which results from overstimulation of sodium channels. Nitric oxide (NO) has recently been implicated in overstimulation of voltage dependent sodium channels. The compounds of the invention can therefore be used to protect cells against NO mediated damage resulting from the overstimulation of voltage dependent sodium channels.

The compounds of the invention are, in particular, effective in protecting neuronal white matter, or myelin coated nerve cell fibres. They therefore have a neuroprotective effect on ganglion cells and axons and can be used in the treatment or prevention of an affective disorder, an anxiety disorder, a behavioural disorder, a

-36-

cardiovascular disorder, a central or peripheral nervous system degenerative disorder, a central nervous system injury, a cerebral ischaemia, a chemical injury or substance abuse disorder, a cognitive disorder, an eating disorder, an eye disease, Parkinson's disease, pain or a seizure disorder.

5 Examples of affective disorders which can be treated or prevented with the compounds of the invention include mood disorders, bipolar disorders (both Type I and Type II) such as seasonal affective disorder, depression, manic depression, atypical depression and monodepressive disease, schizophrenia, psychotic disorders, mania and paranoia.

10 Examples of anxiety disorders which can be treated or prevented with the compounds of the invention include generalised anxiety disorder (GAD), panic disorder, panic disorder with agoraphobia, simple (specific) phobias (e.g. arachnophobia, performance anxiety such as public speaking), social phobias, post-traumatic stress disorder, anxiety associated with depression, and obsessive compulsive disorder (OCD).

15 Examples of behavioural disorders which can be treated or prevented with the compounds of the invention include behavioural and psychological signs and symptoms of dementia, age-related behavioural disorders, pervasive development disorders such as autism, Aspergers Syndrome, Retts syndrome and disintegrative disorder, attention deficit disorder, aggressivity, impulse control disorders and
20 personality disorder.

 Examples of cardiovascular disorders which can be treated or prevented with the compounds of the invention include atherosclerosis, cardiac arrest, thrombosis, complications arising from coronary artery bypass surgery, myocardial infarction, reperfusion injury, intermittant claudication, ischaemic retinopathy, angina, pre-
25 eclampsia, hypertension, congestive cardiac failure, restenosis following angioplasty, sepsis and septic shock.

 Examples of central and peripheral nervous system degenerative disorders which can be treated or prevented with the compounds of the invention include corticobasal degeneration, demyelinating disease such as multiple sclerosis and
30 disseminated sclerosis, Freidrich's ataxia, motoneurone diseases such as

-37-

amyotrophic lateral sclerosis and progressive bulbar atrophy, multiple system atrophy, myelopathy, radiculopathy, peripheral neuropathies such as diabetic neuropathy, tabes dorsalis, drug-induced neuropathy and vitamin deficiency, systemic lupus erythematosus, granulomatous disease, olivo-ponto-cerebellar

5 atrophy, progressive pallidal atrophy, progressive supranuclear palsy and spasticity.

Examples of central nervous system injuries which can be treated with the compounds of the invention include traumatic brain injury, neurosurgery (surgical trauma), neuroprotection for head injuries, raised intracranial pressure, cerebral oedema, hydrocephalus and spinal cord injury.

10 Examples of cerebral ischaemias which can be treated or prevented with the compounds of the invention include transient ischaemic attack, stroke, for example thrombotic stroke, ischaemic stroke, embolic stroke, haemorrhagic stroke or lacunar stroke, subarachnoid haemorrhage, cerebral vasospasm, peri-natal asphyxia, drowning, cardiac arrest and subdural haematoma.

15 Examples of chemical injuries and substance abuse disorders which can be treated or prevented with the compounds of the invention include drug dependence, for example opiate dependence, benzodiazepine addiction, amphetamine addiction and cocaine addiction, alcohol dependence, methanol toxicity, carbon monoxide poisoning and butane inhalation.

20 Examples of cognitive disorders which can be treated or prevented with the compounds of the invention include dementia, Alzheimers Disease, Frontotemporal dementia, multi-infarct dementia, AIDS dementia, dementia associated with Huntingtons Disease, Lewy body Dementia, Senile dementia, age-related memory impairment, cognitive impairment associated with dementia, Korsakoff syndrome
25 and dementia pugilans.

Examples of eating disorders which can be treated or prevented with the compounds of the invention include anorexia nervosa, bulimia, Prader-Willi syndrome and obesity.

30 Examples of eye diseases which can be treated or prevented with the compounds of the invention include drug-induced optic neuritis, cataract, diabetic

-38-

neuropathy, ischaemic retinopathy, retinal haemorrhage, retinitis pigmentosa, acute glaucoma, in particular acute normal tension glaucoma, chronic glaucoma, in particular chronic normal tension glaucoma, macular degeneration, retinal artery occlusion and retinitis.

5 Examples of Parkinson's diseases which can be treated or prevented with the compounds of the invention include drug-induced Parkinsonism, post-encephalitic Parkinsonism, Parkinsonism induced by poisoning (for example MPTP, manganese or carbon monoxide poisoning), Dopa-responsive dystonia-Parkinsonism, post-traumatic Parkinson's disease (punch-drunk syndrome), Parkinson's with on-off
10 syndrome, Parkinson's with freezing (end of dose deterioration) and Parkinson's with prominent dyskinesias.

 Examples of pains which can be treated or prevented with the compounds of the invention include acute pain (e.g. musculoskeletal and post-operative pain) and chronic pain such as osteoarthritis, neuropathic pain, cancer pain, trigeminal
15 neuralgia, migraine and other conditions associated with cephalic pain, primary and secondary hyperalgesia, inflammatory pain, nociceptive pain, tabes dorsalis, phantom limb pain, spinal cord injury pain, central pain, post-herpetic pain and HIV pain, non-cardiac chest pain, irritable bowel syndrome and pain associated with bowel disorders and dyspepsia.

20 Examples of seizure disorders which can be treated or prevented with the compounds of the invention include epilepsy and post-traumatic epilepsy, partial epilepsy (simple partial seizures, complex partial seizures, and partial seizures secondarily generalised seizures), generalised seizures, including generalised tonic-clonic seizures (grand mal), absence seizures (petit mal), myoclonic seizures, atonic
25 seizures, clonic seizures, and tonic seizures, Lennox Gastaut, West Syndrome (infantile spasms), multiresistant seizures and seizure prophylaxis (anti-epileptogenic).

 The compounds of the invention are particularly effective in protecting ganglion cells and axons of the optic nerve from damage. They are therefore
30 particularly effective in the treatment or prevention of glaucoma, for example acute

-39-

glaucoma or chronic glaucoma. As the compounds of the invention are effective as neuroprotectors for white matter, they can be used specifically in the treatment or prevention of normal tension, or normal pressure, glaucoma. Accordingly, when the compounds of the invention are used in the treatment or prevention of glaucoma, they are preferably used in the treatment or prevention of normal tension, or normal pressure, glaucoma.

As is evident from the discussion above, the compounds of the invention are, of course, also useful in the treatment or prevention of diseases other than glaucoma which are attributable to overstimulation of voltage dependent sodium channels. The said 1-benzyl-3-(furanly, phenyl, pyrrolyl or thienyl)-indazoles are preferred in this latter regard, as are the said 1-benzyl-3-aryl-indazoles and 1-benzyl-3-heteroaryl-indazoles.

A further preferred use of the compounds of the invention is in the treatment or prevention of multiple sclerosis.

As explained above, certain compounds of the invention are known as activators of soluble guanylate cyclase (sGC). In one embodiment, the present invention provides a compound of formula (I), as defined above, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in blocking voltage dependent sodium channels, wherein the compound of formula (I) or the salt thereof does not activate sGC. Such compounds may have fewer side effects when used to protect neuronal white matter in accordance with the invention.

An enzyme immunoassay to measure changes in cGMP can be conducted to assess the ability of a compound to activate sGC. To perform the assay, recombinant sGC can be added to 1.1 mg/ml IBMX, 2.6 mg/ml GTP, 667 nM DeaNO and the test compound (10 μ M). The mixture can then be incubated at room temperature for 10 minutes. Compounds can be formulated in DMSO diluted in Tris HCl (pH 7.4) buffer and with a final DMSO concentration of <0.5%.

To determine the amount of cGMP produced, the BiotrakTM cGMP enzyme immunoassay system commercially available from AmershamTM can be used.

The assay is based on the competition between unlabelled cGMP and a fixed

-40-

quantity of peroxidase labelled cGMP for a limited amount of cGMP specific antibody. The peroxidase ligand that is bound to the antibody is immobilised on precoated microtitre wells. The amount of labelled cGMP is determined using a one pot stabilised substrate. The concentration of unlabelled cGMP in a sample is
5 determined by interpolation from a standard curve.

As used herein, a compound which "does not active sGC" typically achieves a cGMP change in the above assay, with 1 μ M test compound in the absence of a NO donor, of less than 120% of the DEANO response, preferably 100% or less than the DEANO response.

10 The compounds of the invention may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules. The compounds of the invention may also be administered parenterally, either subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by
15 infusion techniques. The compounds may also be administered as suppositories.

A compound of the invention is typically formulated for administration with a pharmaceutically acceptable carrier or diluent. For example, solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic
20 acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and
25 pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar-coating, or film coating processes.

Liquid dispersions for oral administration may be syrups, emulsions and suspensions. The syrups may contain as carriers, for example, saccharose or
30 saccharose with glycerine and/or mannitol and/or sorbitol.

-41-

Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.

Solutions for intravenous or infusions may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.

10 A therapeutically effective amount of a compound of the invention is administered to a patient. A typical daily dose is from about 0.1 to 50 mg per kg of body weight, according to the activity of the specific compound, the age, weight and conditions of the subject to be treated, the type and severity of the disease and the frequency and route of administration. Preferably, daily dosage levels are from 5 mg
15 to 2 g.

Certain compounds of the invention have not previously been disclosed in a therapeutic context. Accordingly, the present invention provides a compound of formula (I), as defined above, or a pharmaceutically acceptable salt thereof, for use in the treatment of the human or animal body, excluding:

- 20 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole
- 1-Benzyl-1-3-(5''-methoxycarbonylfuryl)-indazole
- 1-Benzyl-3-(5''-methoxycarbonyl-2-furyl)-6-methylindazole
- 1-Benzyl-3-(5''-methoxycarbonyl-2-furyl)-6-methoxyindazole
- 1-Benzyl-3-(5''-methoxycarbonyl-2-furyl)-6-fluoroindazole
- 25 1-Benzyl-3-(p-ethoxycarbonylphenyl)indazole
- 1-Benzyl-3-(5''-hydroxycarbonyl-2-furyl)-indazole
- 1-Benzyl-3-(5''-hydroxycarbonylfuryl)-6-methylindazole
- 1-Benzyl-3-(5''-hydroxycarbonylfuryl)-6-methoxyindazole
- 1-Benzyl-3-(5''-hydroxycarbonylfuryl)-6-fluoroindazole
- 30 1-Benzyl-3-(5''-hydroxycarbonylfuryl)-indazole

- 1-Benzyl-3-(5''-hydroxymethylfuryl)-indazole
1-Benzyl-3-(5''-hydroxymethylfuryl)-6-methylindazole
1-Benzyl-3-(5''-hydroxymethylfuryl)-6-methoxyindazole
1-Benzyl-3-(5''-hydroxymethylfuryl)-6-fluoroindazole
5 1-Benzyl-3-(p-hydroxymethylphenyl)indazole
1-(2-Fluorobenzyl)-3-(5-hydroxymethylfuran-2-yl)indazole
1-(2-Methoxybenzyl)-3-(5-hydroxymethylfuran-2-yl)-indazole
1-(4-Methoxybenzyl)-3-(5-hydroxymethylfuran-2-yl)-indazole
3-(5-(1,3-Dioxolan-2-yl)furan-2-yl)indazole
10 1-(2-Cyanobenzyl)-3-(5-(1,3-dioxolan-2-yl)furan-2-yl)-indazole
1-(2-Cyanobenzyl)-3-(5-formyl-2-furanyl)-indazole
1-(2-Cyanobenzyl)-3-(5-hydroxymethylfuran-2-yl)-indazole
1-Benzyl-3-[5-(1,3-dioxolan-2-yl)-furan-2-yl]-indazole
1-Benzyl-3-(5-formylfuran-2-yl)-indazole
15 1-[5-(1-Benzylindazole-3-yl)-furan-2-yl]-ethanol
3-(5-Acetylfuran-2-yl)-1-benzyl-indazole
3-(5-Azidomethylfuran-2-yl)-1-benzyl-indazole
3-(5-Aminomethylfuran-2-yl)-1-benzyl-indazole
1-Benzyl-3-(5-nitrofuran-2-yl)-indazole
20 5-[1-(2-Nitro-benzyl)-1H-indazol-3-yl]-furan-2-carbaldehyde
3-[3-(5-Formyl-furan-2-yl)-indazol-1-ylmethyl]-benzonitrile
5-[1-(4-Fluoro-benzyl)-1H-indazol-3-yl]-furan-2-carbaldehyde
1-(2,4-Dichloro-benzyl)-3-(5-[1,3]dioxan-2-yl-furan-2-yl)-1H-indazole
3-(5-[1,3]Dioxan-2-yl-furan-2-yl)-1-(4-fluoro-benzyl)-1H-indazole
25 Acetic acid 5-(1-benzyl-1H-indazol-3-yl)-furan-2-ylmethyl ester
1-Benzyl-3-[5-(tert-butyl-dimethyl-silanyloxymethyl)-furan-2-yl]-1H-indazole
E-5-(1-Benzyl-1H-indazol-3-yl)-furan-2-carbaldehyde oxime
5-(1-Benzyl-6-methoxy-1H-indazol-3-yl)-furan-2-carbaldehyde
30 Acetic acid 5-(1-benzyl-6-methoxy-1H-indazol-3-yl)-furan-2-ylmethyl ester

-43-

- 5-[1-(2,4-Dichloro-benzyl)-1H-indazol-3-yl]-furan-2-carbaldehyde
- 5-[1-(3,5-Dimethyl-benzyl)-1H-indazol-3-yl]-furan-2-carbaldehyde
- 5-(1-Benzyl-1H-indazol-3-yl)-thiophene-2-carbaldehyde
- 5-(1-Benzyl-6-methoxy-1H-indazol-3-yl)-furan-2-carbaldehyde oxime
- 5 (5-(1-Benzyl-1H-indazol-3-yl)-furan-2-carbaldehyde oxime
- 4-[3-(5-Formyl-furan-2-yl)-indazol-1-ylmethyl]-benzonitrile
- 5-[1-(2-Fluoro-benzyl)-1H-indazol-3-yl]-furan-2-carbaldehyde
- 1-Benzyl-3-(5-oxiranylmethoxymethyl-furan-2-yl)-1H-indazole
- 1-Benzyl-3-(5-methoxymethoxymethyl-furan-2-yl)-1H-indazole
- 10 5-[1-(3-Methoxy-benzyl)-1H-indazol-3-yl]-furan-2-carbaldehyde

Preferred compounds for use in the treatment of the human or animal body by therapy are compounds of formula (I), as defined above, and pharmaceutically acceptable salts thereof, wherein, when R_1 is benzyl and R_3 and R_4 , together with the carbon atoms to which they are attached, form a phenyl group, R_2 is not furanyl or phenyl. More preferably, R_2 is not furanyl, phenyl, pyrrolyl or thienyl. Further preferred compounds for use in the treatment of the human or animal body are compounds of formula (I) in which R_3 and R_4 do not together form a phenyl group.

Particularly preferred compounds for use in the treatment of the human or animal body by therapy are compounds of formula (I), as defined above, and pharmaceutically acceptable salts thereof, wherein, when R_2 is a heteroaryl group, it is an oxadiazolyl group. More preferably, R_2 is aryl, 3- to 6- membered heterocyclyl, C_3 - C_6 carbocyclyl or -XR wherein X is a divalent C_1 - C_6 alkyl, C_2 - C_6 alkenyl or C_2 - C_6 alkynyl group and R is aryl, heteroaryl, 3- to 6- membered heterocyclyl or C_3 - C_6 carbocyclyl, or R_2 is C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl or -COR, -CONR'R'' or -CO₂R' wherein each R' and R'' is the same or different and is selected from hydrogen, C_1 - C_6 alkyl and aryl and R is selected from C_1 - C_6 or aryl.

Certain compounds of the invention are novel. These compounds are set out in claim 14. Preferred novel compounds are compounds of the formula (I), as defined above, and pharmaceutically acceptable salts thereof, wherein:

- 30 (a) when R_1 is benzyl and R_3 and R_4 , together with the carbon atoms to

-44-

which they are attached, form a phenyl group, R_2 is not furanyl or phenyl; and

- (b) when R_1 is benzyl, t-butyl, methyl or ethyl, R_2 is t-butyl, -CONH-phenyl or methyl and R_3 is hydrogen, R_4 is not -CONHPh, -CONH-NHCO-Ph, -CONH-NH-CO-NHPh, -CONH₂, methyl, triazolyl, -CONH-NH-COtBu or -CONH-NH-CS-NHMe.

More preferably, under the circumstances set out in (a) above, R_2 is not furanyl, phenyl, pyrrolyl or thienyl. Further it is preferred that when R_1 is benzyl or C₁-C₄ alkyl, R_2 is -CONH-aryl or C₁-C₄ alkyl and R_3 is hydrogen, R_4 is not C₁-C₄ alkyl, heterocyclyl or a substituted or unsubstituted amide moiety.

- 10 Particularly preferred novel compounds of the invention are compounds of formula (I) in which R_3 and R_4 , together with the carbon atoms to which they are attached, form a phenyl group (i.e. indazole compounds) and in which R_1 and R_2 are as defined above, provided that when R_1 is benzyl, R_2 is not furanyl or phenyl. Of these compounds, compounds in which R_2 is not furanyl, phenyl, pyrrolyl or thienyl
15 are more preferred.

The Examples which follow illustrate the invention.

Preparation Example 1**5-Methoxycarbonyl-2-furyl-2-nitrophenyl ketone**

A suspension of 2-nitrobenzoic acid (30.0 g, 0.18 mol) in thionyl chloride
5 (100 mL) with a catalytic amount of N,N-dimethylformamide (50 μ L) was heated to reflux for 2 h. After cooling, the excess thionyl chloride was removed under reduced pressure. The residual oil was dissolved in CH_2Cl_2 (100 mL) and to this solution was added FeCl_3 (0.60 g, 3.70 mmol) portion-wise followed by methyl furanoate (22 mL, 0.21 mol). The resultant mixture was heated to reflux for 15 h. A further portion of
10 FeCl_3 (0.60 g, 3.70 mmol) was added to the mixture and heating continued for a further 4 h. The mixture was allowed to cool to ambient temperature and then poured onto water (100 mL). The layers were separated and the aqueous layer was extracted with CH_2Cl_2 three times. The combined organic material was washed three times with saturated aqueous NaHCO_3 , dried (MgSO_4) and concentrated under
15 reduced pressure. The crude material was initially purified through a plug of silica using a cyclohexane-EtOAc gradient, then the solid was recrystallised from hexane/ CH_2Cl_2 to provide the product as fine yellow needles (14.97 g, 30%): mp 137-138°C; MS [EI] ($\text{M} - \text{OCH}_3$)⁺ 244; ^1H -NMR (CDCl_3) 3.90 (s, 3H), 7.24 (m, 2H), 7.61 (dd, 1H, $J=7.4, 1.5$ Hz), 7.74 (m, 1H), 7.82 (m, 1H), 8.25 (dd, 1H, $J=8.1, 1.1$ Hz);
20 Anal. ($\text{C}_{13}\text{H}_9\text{NO}_6$) C, calcd 56.73; found 56.48, H, calcd 3.30; found 2.90, N, calcd 5.09; found 4.95.

Preparation Example 2**5-Methoxycarbonyl-2-furyl-2-aminophenyl ketone**

Iron powder (7.7 g, 0.14 mol) was added in three portions to a solution of 5-methoxycarbonyl-2-furyl 2-nitrobenzyl ketone (7.0 g, 25.4 mmol) in acetic acid (500 mL) containing water (15 mL) at a temperature of 90°C. The mixture was then heated to reflux for 5 h, whereupon TLC analysis indicated the reaction to be complete. The excess acetic acid was removed by rotary evaporation under reduced pressure. Water (400 mL) was added to the residue and the mixture was stirred vigorously for 1 h. The mixture was then basified by the addition of concentrated aqueous ammonia solution and the resultant suspension was filtered through celite. The celite 'cake' was washed with water followed with copious amounts of CH₂Cl₂. The combined filtrate layers were separated and the aqueous layer extracted five times with CH₂Cl₂. The combined organic material was dried (MgSO₄) and concentrated under reduced pressure to give a dark orange solid (5.23 g, 84%). This material was used without further purification in subsequent reactions. A small amount was recrystallised (hexane) to give an orange powder for analysis: mp 104-106°C; MS [EI] (M⁺) 245; ¹H-NMR (CDCl₃) 3.96 (s, 3H), 6.10 (bs, 2H), 6.74 (m, 2H), 7.18 (d, 1H, J=3.7 Hz), 7.29 (m, 1H), 7.34 (m, 1H), 8.01 (dd, 1H, J=8.1, 1.4 Hz); Anal. (C₁₃H₁₁NO₄) C, calcd 63.67; found 63.48, H, calcd 4.52; found 4.40, N, calcd 5.71; found 5.66.

-47-

Preparation Example 3**5-Methoxycarbonyl-2-furyl-2-aminophenyl ketone**

To a solution of 5-methoxycarbonyl-2-furyl 2-nitrophenyl ketone (0.54 g, 1.96 mmol) in EtOAc (100 mL) was added $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ (1.35 g, 5.98 mmol) and the resultant solution was allowed to stir at rt for 48 h. Reaction mixture poured onto 10% aqueous NH_3 solution, mixture shaken and then layers separated. The aqueous layer was extracted twice with EtOAc. The combined organic material was dried (MgSO_4) and concentrated under reduced pressure. Generally the crude, orange solid (0.54 g) was used without further purification. If the reaction was heated overnight (5/97/61) then a significant amount of the byproduct, 3-(5'-methoxycarbonyl-2'-furyl)benzisoxazole, was formed.

Example 1**3-(5-Methoxycarbonyl-2-furyl)-1H-indazole**

Crude 5-Methoxycarbonyl-2-furyl 2-aminobenzyl ketone (0.54 g, 1.96 mmol) was dissolved in conc. HCl (15 mL) and cooled to -10°C . A solution of NaNO_2 (0.15 g, 2.17 mmol) in water (2 mL) was added and the mixture stirred for 1 h, maintaining a temperature of -10°C . A solution of tin (II) chloride dihydrate (1.10 g, 4.88 mmol) in conc. HCl (2mL) was then added followed by a further 1 h of stirring at -10°C . Ice-water (100 mL) was added and the suspension was extracted three times with EtOAc. The combined extracts was washed with water, dried (MgSO_4) and concentrated under reduced pressure. The crude product was purified by passage through a silica plug using a gradient of cyclohexane-EtOAc and then recrystallised (acetone/ H_2O) to give the product as a yellow, fluffy solid (0.38 g, 79%): mp $157-159^\circ\text{C}$; MS (EI) M^+ 242; ^1H -NMR (DMSO) 4.00 (s, 3H), 7.31 (d, 1H, J 3.8 Hz), 7.42 (t, 1H, J 7.3 Hz), 7.58 (t, 1H, J 7.9 Hz), 7.61 (d, 1H J 3.8 Hz), 7.76 (d, 1H, J 8.3 Hz), 8.26 (d, 1H, J 8.3 Hz); ^{13}C -NMR (CDCl_3) 51.90, 108.36, 109.89, 119.72, 120.49, 121.66, 122.34, 127.50, 141.04, 143.75, 152.72, 159.20; Anal. ($\text{C}_{13}\text{H}_{10}\text{N}_2\text{O}_3$) C, calcd 64.46; found 64.32, H, calcd 4.16; found 4.30, N, calcd 11.56; found 11.13.

Example 2**1-Benzyl-3-(5-methoxycarbonyl-2-furyl)-1H-indazole**

A solution of 3-(5-methoxycarbonyl-2-furyl)-1H-indazole (2.0 g, 8.3 mmol) and benzyl bromide (2.5 mL, 21.0 mmol) in THF (100 mL) was added dropwise *via* dropping funnel to a suspension of sodium hydride (60% dispersion in oil: 0.50 g, 12.5 mmol) in THF (200 mL). The resultant mixture was stirred at room temperature for 20 h. The mixture was poured onto brine and the layers separated. The aqueous layer was extracted three times with ether and then the combined organic material was washed with saturated aqueous NaHCO₃ solution, dried (MgSO₄) and concentrated under reduced pressure. The residue was chromatographed on silica (EtOAc:cyclohexane 1:4) and then the product was recrystallised (EtOAc/hexane) to give a yellow solid: mp 137-138°C; MS (EI) M⁺ 332; ¹H-NMR (CDCl₃) 3.97 (s, 3H), 5.67 (s, 2H), 7.03 (d, 1H, J=3.7 Hz), 7.22-7.43 (m, 9H), 8.27 (d, 1H, J=8.1 Hz); Anal. (C₂₀H₁₆N₂O₃) C, calcd 72.28; found 71.92, H, calcd 4.85; found 4.75, N, calcd 8.43; found 8.39.

Example 3**1-Benzyl-3-(5-methoxycarbonyl-2-furyl)-1H-indazole**

3-Iodo-1H-indazole was prepared using the method of Auwers *et al. J. Prakt. Chem.* 1924, 108, 314: mp 141 - 142 °C, lit. mp 142 °C.

To prepare 1-Benzyl-3-iodo-1H-indazole (CFM793), sodium hydride (60% dispersion in mineral oil) (0.36 g, 9.02 mmol) was stirred under nitrogen in anhydrous THF (10 mL) and the solution was cooled to 0 °C. 3-Iodo-1H-indazole (2.0 g, 8.20 mmol) was dissolved in THF (30 mL) and this solution was syringed into the flask. The reaction mixture was kept at 0 °C while benzyl bromide (1.54 g, 9.02 mmol) was syringed slowly into the flask. The reaction mixture was stirred at 0 °C for 30 minutes then it was warmed to room temperature and kept at this temperature for 48 hours. Water (20 mL) was added slowly and then the mixture was poured onto brine. The organic product was extracted using ethyl acetate (3 × 50 mL). The

-49-

combined ethyl acetate extracts were dried over MgSO_4 , filtered and concentrated under reduced pressure. The resulting solid was recrystallised from ethanol to give 1.39g, 52 %: mp 54-55 °C; ^1H NMR (300 MHz, CDCl_3) δ 7.42 - 7.40 (m, 2H), 7.33 - 7.09 (m, 7H), 5.53 (s, 2H); MS (EI) m/z 334 [M^+]; Anal. $\text{C}_{14}\text{H}_{11}\text{N}_2\text{I}$ calculated C, 50.31; H, 3.29; N, 8.39; found C, 51.05; H, 3.25; N, 8.00.

A solution of methyl 5-bromofuranoate (0.75 g, 3.66 mmol), hexamethylditin (1.0 g, 3.05 mmol) and $\text{Pd}(\text{PPh}_3)_4$ (90 mg, 0.078 mmol) in DME (50 mL) was heated to reflux overnight. The initial amber coloured solution became black. The solution was allowed to cool and then filtered and concentrated under reduced pressure. The crude stannane was purified by passage through a plug of silica (1:9 EtOAc:cyclohexane) to give methyl 2-trimethylstannyl-5-furanoate (0.17 g, 19%): ^1H -NMR (CDCl_3) ; The low yield of the product may be due to its suspected volatility. $\text{Pd}(\text{PPh}_3)_4$ (9 mg, 0.008 mmol) was added to a solution of 1-benzyl-3-iodo-1H-indazole (0.13 g, 0.39 mmol) and methyl 2-trimethylstannyl-5-furanoate (0.17 g, 0.588 mmol) in DME (20 mL) and the mixture was heated to reflux overnight. The reaction mixture was allowed to cool to rt, filtered and concentrated under reduced pressure. Purification of the residue by chromatography on silica (3:7 EtOAc:cyclohexane) gave the product as a slightly contaminated yellow solid (88.6 mg, 69%).

20

Example 4

1-Benzyl-3-(5-hydroxymethyl-2-furyl)-1H-indazole

A solution of 1-benzyl-3-(5-methoxycarbonyl-2-furyl)-1H-indazole in THF (150 mL) was added dropwise to a suspension of $\text{CaBH}_4 \cdot 2\text{THF}$ (3.9 g, 18.23 mmol) in THF (150 mL) at room temperature. The resultant mixture was heated to reflux for 15 h. The reaction mixture was allowed to cool, then poured slowly onto brine. The layers were separated and the aqueous layer was extracted three times with ether. The combined organic material was dried (MgSO_4) and concentrated under reduced pressure. The crude product was chromatographed on silica (30-40% EtOAc/cyclohexane) and then recrystallised (ethanol/ H_2O) to give the product as fine

30

-50-

cream needles (1.56 g, 86%): mp 112-112.5°C (lit. mp 108-109°C); MS (EI) M^+ 304; ^1H -NMR (CDCl_3) 4.76 (s, 2H), 5.68 (s, 2H), 6.50 (d, 1H, $J=3.3$ Hz), 6.90 (d, 1H, $J=3.3$ Hz), 7.21-7.40 (m, 8H), 8.08 (d, 1H, $J=8.5$ Hz); ^{13}C -NMR (CDCl_3) 54.12, 58.53, 108.87, 110.57, 110.59, 122.25, 122.38, 122.50, 127.83, 128.00(2C), 128.72, 129.68(2C), 137.14, 137.53, 141.45, 149.52, 154.88; Anal. ($\text{C}_{19}\text{H}_{16}\text{N}_2\text{O}_2$) C, calcd 74.98; found 74.80, H, calcd 5.30; found 5.28, N, calcd 9.20; found 9.15.

Example 5

1-Benzyl-3-(5-hydroxycarbonyl-2-furyl)-1H-indazole

10 A mixture of 1-benzyl-3-(5-methoxycarbonyl-2-furyl)-1H-indazole (1.46 g, 4.39 mmol), 15% aqueous KOH solution (100 mL) and methanol (100 mL) was heated to reflux for 4 h. The resultant solution was allowed to cool and then diluted with H_2O (300 mL). The solution was acidified to pH 2 by the addition of conc. HCl and the precipitate collected by vacuum filtration. The off-white solid was washed
15 with H_2O and air dried. Recrystallisation of the crude solid (EtOH) gave the product as fine off-white needles (1.16 g, 83%): mp 205-206.5°C (lit mp 200-202°C); ^1H -NMR (DMSO) 5.34 (s, 2H), 6.67 (d, 1H, J 3.6 Hz), 6.89-7.00 (m, 7H), 7.08 (m, 2H), 7.89 (d, 1H, J 8.0 Hz); ^{13}C -NMR (CDCl_3) 52.55, 109.06, 110.91, 119.84, 120.91, 121.22, 122.57, 127.49, 127.69(2C), 128.02, 128.99(2C), 134.69, 137.40, 140.72,
20 144.41, 151.75, 159.67; MS (EI) M^+ ; Anal. ($\text{C}_{19}\text{H}_{14}\text{N}_2\text{O}_3$) C, calcd 73.19; found 73.18, H, calcd 7.17; found 7.16, N, calcd 14.23; found 14.13.

Example 6

1-Benzyl-3-(5-hydroxylaminocarbonyl-2-furyl)-1H-indazole

25 A mixture of 1-benzyl-3-(5-hydroxycarbonyl-2-furyl)-1H-indazole (0.40 g, 1.257 mmol), DMF (cat., 2 drops) and SOCl_2 (5 mL) was heated to reflux for 2 h. After cooling, the excess SOCl_2 was removed under reduced pressure and the almost black oil was dissolved in DME (8 mL). A portion of this acid chloride solution (2 mL, approx. 0.314 mmol) was mixed with a solution of $\text{NH}_2\text{OH}\cdot\text{HCl}$ (0.20 g, 2.88
30 mmol) and K_2CO_3 (excess) in H_2O (2 mL) and allowed to stir at rt overnight A

-51-

precipitate formed while stirring. The reaction mixture was poured onto water (50 mL) and extracted four times with EtOAc. The combined organic material was dried (MgSO_4) and concentrated under reduced pressure to give the crude product (77.4 mg, 74%) as an orange/brown solid.

5

Example 7**1-Benzyl-3-(5-hydroxylaminocarbonyl-2-furyl)-1H-indazole**

To a solution of 1-benzyl-3-(5-hydroxycarbonyl-2-furyl)-1H-indazole (0.20 g, 0.63 mmol) and O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium
10 tetrafluoroborate (TBTU) (0.21 g, 0.65 mmol) in anhydrous DMF (3 mL) was added N-methylpiperidine (1.4 mL) dropwise at rt. Stirring was continued for 15 min and then $\text{NH}_2\text{OH}\cdot\text{HCl}$ (44 mg, 0.63 mmol) was added as a solid. The mixture was stirred at rt overnight. Excess DMF was removed by rotary evaporator under high vacuum. The residue was dissolved in EtOAc and washed with a saturated aqueous solution of
15 NaHCO_3 , H_2O , 10% aqueous HCl solution, H_2O , dried (MgSO_4) and concentrated under reduced pressure. The crude solid was recrystallised ($\text{EtOH}/\text{H}_2\text{O}$) to give the product (0.118 g, 56%): mp 138 (dec.); $^1\text{H-NMR}$ (DMSO) 5.75 (s, 2H), 7.13 (d, 1H, J 3.4 Hz), 7.23-7.35 (m, 7H), 7.48 (t, 1H, J 7.7 Hz), 7.79 (d, 1H, J 8.7 Hz), 8.30 (d, 1H, J 7.9 Hz), 9.18 (b, 1H), 11.27 (b, 1H); $^{13}\text{C-NMR}$ (DMSO) ; MS (EI) M^+ 333;
20 Anal. ($\text{C}_{19}\text{H}_{15}\text{N}_3\text{O}_3\cdot\text{H}_2\text{O}$) C, calcd 64.95; found 65.07, H, calcd 4.88; found 4.73, N, calcd 11.96; found 11.83.

Example 8

5-(1-Benzyl-1H-indazol-3-yl)-furan-2-carboxylic acid benzyl-hydroxy-amide
25 **and 5-(1-Benzyl-1H-indazol-3-yl)-furan-2-carboxylic acid N-benzylhydroxylamine ester.**

To the acid 1 mL of a [(159.0 mg, 0.5 mmol) in acetonitrile (5 mL)] solution was added the O-(azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium dextafluorophosphate 1 mL of a [(190.1 mg, 0.5 mmol in acetonitrile (5 mL)]
30 solution and the diisopropylethylamine resin (0.3 mmol, ~100 mg) followed by the

-52-

N-benzylhydroxylamine hydrochloride (16 mg, 0.1 mmol). The reaction was heated to 50° for 4 h. The reaction was allowed to cool and filtered. Tetrafluorophthalic anhydride (66 mg, 0.3 mmol) added and the reaction shaken overnight. Water (1 drop) was added and the reaction shaken for 1 h. Tetraalkylammonium polystyrene
5 resin, PS-carbonate, Argonaut Technologies, (500 mg, ~1.5 mmol) was added and the mixture shaken for 24 h. The resin was filtered off and the solvent removed on the rotary evaporator 31.1 mg. LCMS (C18 column, 0.1% trifluoroacetic acid, acetonitrile/ H₂O) electrospray. m/z 423.42 at 1.69 min and m/z 424 at 3.58 min.

10 Examples 9 to 45

The following compounds were prepared by the technique set out in Example 8. Synthesis was confirmed by LCMS data.

<u>Example</u>	<u>Compound</u>
9	2-Benzyl-5- <i>tert</i> -butyl-2 <i>H</i> -pyrazole-3-carboxylic acid phenylamide
10	2-Benzyl-5- <i>tert</i> -butyl-2 <i>H</i> -pyrazole-3-carboxylic acid benzylamide
11	1-(4-Chloro-phenyl)-5-phenyl-1 <i>H</i> -pyrazole-3-carboxylic acid phenylamide
5	12 5- <i>tert</i> -Butyl-2-(2,4-dichloro-benzyl)-2 <i>H</i> -pyrazole-3-carboxylic acid (4-methoxy-phenyl)-amide
13	2-Ethyl-5-thiophen-2-yl-2 <i>H</i> -pyrazole-3-carboxylic acid (4-chloro-phenyl)-amide
14	(S)-5- <i>tert</i> -Butyl-2-(2,4-dichloro-benzyl)-2 <i>H</i> -pyrazole-3-carboxylic acid (4-chloro-phenyl)-amide
15	5- <i>tert</i> -Butyl-2-(2,4-dichloro-benzyl)-2 <i>H</i> -pyrazole-3-carboxylic acid phenethyl-amide
16	(S)-2-Ethyl-5-thiophen-2-yl-2 <i>H</i> -pyrazole-3-carboxylic acid phenethyl-amide
10	17 5- <i>tert</i> -Butyl-2-(2,4-dichloro-benzyl)-2 <i>H</i> -pyrazole-3-carboxylic acid phenylamide
18	5- <i>tert</i> -Butyl-2-(2,4-dichloro-benzyl)-2 <i>H</i> -pyrazole-3-carboxylic acid benzylamide
19	1-(4-Chloro-phenyl)-5-phenyl-1 <i>H</i> -pyrazole-3-carboxylic acid (4-dimethylamino-phenyl)-amide
20	1-(4-Chloro-phenyl)-5-phenyl-1 <i>H</i> -pyrazole-3-carboxylic acid (4- <i>tert</i> -butyl-phenyl)-amide
21	2- <i>tert</i> -Butyl-5-methyl-2 <i>H</i> -pyrazole-3-carboxylic acid (4- <i>tert</i> -butyl-phenyl)-amide
15	22 2- <i>tert</i> -Butyl-5-methyl-2 <i>H</i> -pyrazole-3-carboxylic acid (3,4-dichloro-phenyl)-amide

5	23	5- <i>tert</i> -Butyl-2-methyl-2 <i>H</i> -pyrazole-3-carboxylic acid (3,4-dichloro-phenyl)-amide
	24	2-Benzyl-5- <i>tert</i> -butyl-2 <i>H</i> -pyrazole-3-carboxylic acid (3,4-dichloro-phenyl)-amide
	25	2-Benzyl-5- <i>tert</i> -butyl-2 <i>H</i> -pyrazole-3-carboxylic acid (4- <i>tert</i> -butyl-phenyl)-amide
	26	5- <i>tert</i> -Butyl-2-methyl-2 <i>H</i> -pyrazole-3-carboxylic acid (4- <i>tert</i> -butyl-phenyl)-amide
	27	2-Benzyl-5- <i>tert</i> -butyl-2 <i>H</i> -pyrazole-3-carboxylic acid (4-dimethylamino-phenyl)-amide
10	26	2-Benzyl-5- <i>tert</i> -butyl-2 <i>H</i> -pyrazole-3-carboxylic acid (3-oxazol-5-yl-phenyl)-amide
	29	5- <i>tert</i> -Butyl-2-methyl-2 <i>H</i> -pyrazole-3-carboxylic acid (3-oxazol-5-yl-phenyl)-amide
	30	1-(4-Chloro-phenyl)-5-phenyl-1 <i>H</i> -pyrazole-3-carboxylic acid (5- <i>tert</i> -butyl-isoxazol-3-yl)-amide
	31	2- <i>tert</i> -Butyl-5-methyl-2 <i>H</i> -pyrazole-3-carboxylic acid (4-phenylcarbamoyl-phenyl)-amide
	32	2-Benzyl-5- <i>tert</i> -butyl-2 <i>H</i> -pyrazole-3-carboxylic acid (3-phenylcarbamoyl-phenyl)-amide
	33	5- <i>tert</i> -Butyl-2-methyl-2 <i>H</i> -pyrazole-3-carboxylic acid (3-phenylcarbamoyl-phenyl)-amide
	34	2-Benzyl-5- <i>tert</i> -butyl-2 <i>H</i> -pyrazole-3-carboxylic acid (6-chloro-pyridin-3-yl)-amide
	35	1- <i>tert</i> -Butyl-5-methyl-1 <i>H</i> -pyrazole-3-carboxylic acid (6-chloro-pyridin-3-yl)-amide
	36	1- <i>tert</i> -Butyl-5-methyl-1 <i>H</i> -pyrazole-3-carboxylic acid (4-acetylamino-phenyl)-amide

37	1- <i>tert</i> -Butyl-5-methyl-1 <i>H</i> -pyrazole-3-carboxylic acid (3-benzyloxy-pyridin-2-yl)-amide
38	5-Methyl-1-(4-methyl-benzyl)-1 <i>H</i> -pyrazole-3-carboxylic acid (4-acetylamino-phenyl)-amide
39	5- <i>tert</i> -Butyl-2-(2,4-dichloro-benzyl)-2 <i>H</i> -pyrazole-3-carboxylic acid (4-acetylamino-phenyl)-amide
40	2-Ethyl-5-thiophen-2-yl-2 <i>H</i> -pyrazole-3-carboxylic acid (4-acetylamino-phenyl)-amide
41	5- <i>tert</i> -Butyl-2-(2,4-dichloro-benzyl)-2 <i>H</i> -pyrazole-3-carboxylic acid (4-(pyridin-3-yl) thiazol-2-yl)-amide
42	2-Ethyl-5-thiophen-2-yl-2 <i>H</i> -pyrazole-3-carboxylic acid (4-(pyridin-3-yl) thiazol-2-yl)-amide
43	2-Benzyl-5- <i>tert</i> -butyl-2 <i>H</i> -pyrazole-3-carboxylic acid (4-acetylamino-phenyl)-amide
44	5- <i>tert</i> -Butyl-2-methyl-2 <i>H</i> -pyrazole-3-carboxylic acid (4-(pyridin-3-yl) thiazol-2-yl)-amide
45	5- <i>tert</i> -Butyl-2-methyl-2 <i>H</i> -pyrazole-3-carboxylic acid [3-(4-methoxy-benzyl)-[1,2,4]oxadiazol-5-yl]-amide

Example 46**[*N*-Ethyl-(4-Aminobutyl)]-1-benzylindazole**

A solution of (3-chloropropyl)indazole (Sasakura et al, *Synth. Comm.*, 18, pg 259 (1988)) (750mg, 3.75 mM) in dimethylformamide (25 ml) was stirred at room temperature and sodium cyanide (370 mg, 7.5 mM) added in one portion. The resulting mixture was heated at 90°C for 4 hr. The dimethylformamide was removed *in vacuo* and the residue partitioned between water and ethyl acetate. The combined organics were dried over magnesium sulfate. Column chromatography (ethyl acetate/cyclohexane, 1:1) provided 3-(3-cyanopropyl)indazole as a clear oil (3.21 g, 83%).

-56-

¹NMR (300MHz, CDCl₃) 7.75 (1H, d, *J* 8Hz), 7.40-7.50 (2H, m), 7.20 (1H, t, *J* 8Hz), 3.18 (2H, t, *J* 6Hz), 2.58 (2H, t, *J* 6Hz), 2.20-2.30 (2H, m). *M/z* = 187 (CI).

A solution of this compound (187mg, 1 mM) in dry tetrahydrofuran (5 ml) was added dropwise to a suspension of sodium hydride (60% in oil, 45 mg, 1.1 mM) in dry tetrahydrofuran (10 ml) at 0°C. After 10 min benzyl bromide (0.13 ml, 188 mg, 1.1 mM) was added and the mixture stirred at 0°C for 30 min then allowed to warm to room temperature and left stirring overnight. Water (2 ml) was added and the tetrahydrofuran removed *in vacuo*. The residue was partitioned between water and ethyl acetate and the combined organics dried over magnesium sulfate and evaporated. Column chromatography (ethyl acetate/cyclohexane, 1:4) provided 1-benzyl-3-(3-cyanopropyl)indazole as a thick yellow oil (180 mg, 63%).

¹NMR (300MHz, CDCl₃) 7.70 (1H, d, *J* 8Hz), 7.10-7.40 (8H, m), 3.15 (2H, t, *J* 6Hz), 2.58 (2H, t, *J* 6Hz), 2.20-2.30 (2H, m).

A solution of 1-benzyl-3-(3-cyanopropyl)indazole (100 mg, 0.35 mM) in ethanol (10 ml) was stirred at room temperature and Raney nickel (approx. 100 mg, wet weight) was added. The resulting suspension was warmed to 65°C and hydrazine hydrate (0.1 ml, 87 mg) added carefully. The mixture was stirred at 70°C for a further 2 hr then cooled and filtered through celite. Solvent was removed *in vacuo* and the residue purified by chromatography on silica (chloroform/methanol 9:1) to give the title product as a clear oil (25 mg, 26%).

¹NMR (300MHz, CDCl₃) 7.60 (1H, d, *J* 8Hz), 6.95-7.25 (8H, m), 5.45 (2H, s), 2.92 (2H, t, *J* 6Hz), 2.50-2.60 (4H, t, *J* 6Hz), 2.15 (1H, bs), 1.75 (2H, m), 1.55 (2H, m), 1.00 (3H, t, *J* 6Hz). *M/z* = 307 (EI). Found C, 74.73; H, 8.16; N, 12.80; C₂₀H₂₅N₃ 0.8 H₂O requires: C, 74.67; H, 8.28; N, 13.07.

Example 47

1-Benzyl-3-[*N*-(2-*N,N*-dimethylaminoethyl)carboxamido]indazole

To a suspension of sodium hydride (60% in oil, 55 mg, 1.22 mM) in dry THF (10 ml) stirring at 0°C was added a solution of methyl indazole-3-carboxylate (von Auwers et al, *Ber.*, 52, pg 1345 (1919), 210 mg, 1.22 mM) in dry THF (10 ml). After

-57-

10 min benzyl bromide (0.15 ml, 1.22 mM) was added and the solution left stirring at room temperature overnight. Water (2 ml) was added and the solvent removed *in vacuo*. The residue was partitioned between water and ethyl acetate and the combined organic dried over magnesium sulfate and evaporated. Column chromatography (ethyl acetate/cyclohexane 1:4) provided methyl 1 benzyl-indazole-3-carboxylate as a yellow powder (250 mg, 77%). M.pt. 181°C.

¹NMR (300MHz, CDCl₃) 8.15 (1H, d, *J* 8Hz), 7.10-7.30 (8H, m), 5.60 (2H, s), 3.95 (3H, s). *M/z* = 266 (EI). Found C, 72.17; H, 5.20; N, 10.50; C₁₆H₁₄N₂O₂ requires: C, 72.18; H, 5.26; N, 10.53.

10 A suspension of methyl 1-benzyl-indazole-3-carboxylate (400 mg, 1.5 mM) in sodium hydroxide (1N, 10 ml) was heated at 80°C for 2 hr to give a clear solution. The cooled solution was washed with ethyl acetate then the aqueous layer adjusted to pH 5 with 1N hydrochloric acid. 1-Benzyl indazole-3-carboxylic acid was extracted into ethyl acetate, dried over magnesium sulfate, then evaporated to give a white powder (310 mg, 82%). M.pt. 169-171°C.

¹NMR (300MHz, CDCl₃) 8.28 (1H, d, *J* 8Hz), 7.20-7.50 (8H, m), 5.70 (2H, s). *M/z* = 252 (EI). Found C, 70.80; H, 4.71; N, 10.91; C₁₅H₁₂N₂O₂ requires: C, 71.43; H, 4.76; N, 11.11.

20 A solution of 1-benzyl indazole-3-carboxylic acid (25.2 mg, 0.1 mM) in acetonitrile (10 ml) was stirred and HATU (38 mg, 0.1 mM) added. DIPEA resin (0.3 mM, 80 mg) was added followed by *N,N* dimethylethylenediamine (8.8 mg, 0.1 mM). The resulting mixture was heated at 50°C for 5 hr. Tetrafluorophthallic anhydride (66 mg, 0.3 mM) was added and the mixture stirred for a further 24 hr. Carbonate resin (630 mg, 2.0 mM) was added and stirring continued for 48 hr and the mixture was then filtered through a short silica column to give, after evaporation *in vacuo*, the title compound as a thick oil (17 mg, 53%).

25 ¹NMR (300MHz, CDCl₃) 8.50 (1H, d, *J* 8Hz), 7.20-7.50 (8H, m), 5.70 (2H, s), 3.70 (2H, m), 2.68 (2H, m), 2.40 (6H, s). *M/z* = 323 (EI+ve, LC/MS in TFA). Found C, 70.65; H, 6.98; N, 17.16; C₁₉H₂₂N₄O₂ requires: C, 70.81; H, 6.83; N, 17.39.

-58-

Example 48**Indazole-3-carboxylic acid**

Isatin (10 g, 0.067 mol) was added to a solution of NaOH (2.8 g, 0.07 mol) in H₂O (44 mL) at 50 °C. The stirred clear solution was cooled to 0 °C and a solution of sodium nitrite (4.69 g, 0.067 mol) in H₂O (17 mL) was added and stirring continued. A solution of concentrated H₂SO₄ (12.9 g) in H₂O (136 mL) was cooled to 0 °C and added dropwise to the reaction mixture in such a way that the dropper was below the level of the reaction mixture. Stirring was continued for 15 min and a cooled solution of tin(II) chloride dihydrate (36.7 g, 0.16 mol) in concentrated HCl (58 mL) was added over 20 min. The reaction mixture was stirred for 1 h and the orange solid was filtered then heated in H₂O at 100 °C. The insoluble solids were removed by filtration and the product crystallised from the solution affording the title compound as a yellow solid (3.4 g, 31%). Mp 261-263 °C d, lit 260-261 °C v. Auwers, Dereser *Chem. Ber.* 1919, 52, 1343. ¹H NMR (300 MHz, DMSO-*d*₆) ppm 7.26-7.31 (m, 1H), 7.40-7.46 (m, 1H), 7.63-7.66 (m, 1H), 8.08-8.10 (m, 1H), 12.95 (s, 1H), 13.80 (s, 1H). MS(EI) *m/z* 162 [M⁺].

Example 49**Indazole-3-carboxylic acid methyl ester**

Concentrated H₂SO₄ (1 mL) was added to a solution of indazole-3-carboxylic acid (2.0 g, 12 mmol) in MeOH (40 mL). The reaction mixture was heated at reflux for 3 h, the MeOH was removed under reduced pressure and the residue was partitioned between diethyl ether (100 mL) and H₂O (100 mL). Saturated sodium hydrogen carbonate solution was added (100 mL) and the diethyl ether layer was separated. The aqueous layer was further extracted with 2 × 200 mL of diethyl ether. The combined extracts were dried (MgSO₄) and solvent removed under reduced pressure and the solid was recrystallised from cyclohexane/ethyl acetate to afford the title compound (1.29 g, 61%). Mp 158-159 °C, lit 168-169 °C v. Auwers, Dereser *Chem. Ber.* 1919, 52, 1343. ¹H-NMR (300 MHz, CDCl₃) ppm 4.09 (s, 3H), 7.33-7.38 (m, 1H), 7.46-7.52 (m, 1H), 7.71-7.74 (m, 1H), 8.23-8.26 (m, 1H), 12.03 (s, 1H). MS(EI) *m/z* 176 [M⁺].

Example 50**1-Benzylindazole-3-carboxylic acid methyl ester**

Sodium hydride (0.37 g, 60%, 9.3 mmol) was added to a solution of indazole-3-carboxylic acid methyl ester (1.5 g, 8.5 mmol) in dry THF (50 mL) at 0 °C. Benzyl bromide (1.59 g, 9.3 mmol) was then added and the reaction mixture was warmed to 25 °C and stirred for 8 h. The reaction mixture was poured onto saturated NaCl solution (100 mL) and extracted with 3 × 200 mL of diethyl ether. The combined extracts were dried (MgSO₄) and concentrated under reduced pressure. The crude compound was purified by flash chromatography using cyclohexane/ethyl acetate (70:30) and recrystallised from cyclohexane/ethyl acetate to afford the title compound as a yellow solid (1.89 g, 84%). Mp 72-73 °C. ¹H NMR (300 MHz, CDCl₃) ppm 4.07 (s, 3H), 5.72 (s, 2H), 7.22-7.40 (m, 8H), 8.24-8.27 (m, 1H). MS(EI) *m/z* 266 [M⁺]. Anal. Calcd. for C₁₆H₁₄N₂O₂: C, 72.17; H, 5.30; N, 10.52. Found: C, 72.12; H, 5.15; N, 10.85.

Example 51**1-Benzyl-3-[3-aminomethyl-1,2,4-oxadiazol-5-yl]indazole**

A solution of aminoacetonitrile hydrochloride (0.5 g, 5.4 mmol) and sodium (0.124 g, 5.4 mmol) in MeOH (15 mL) was added to a solution of hydroxylamine hydrochloride (0.37 g, 5.4 mmol) and sodium (0.124 g, 5.4 mmol) in MeOH. The reaction mixture was refluxed for 4 h then filtered and concentrated under reduced pressure. The crude material was taken up in dry THF (30 mL), sodium hydride (0.114 g, 60%, 2.86 mmol) was added and the reaction mixture heated at 60 °C. 1-Benzylindazole-3-carboxylic acid methyl ester (0.25 g, 0.938 mmol) was added and the reaction mixture was heated at reflux for 4 h. The THF was removed under reduced pressure and the residue partitioned between chloroform (100 mL) and H₂O (100 mL). The chloroform layer was separated and the aqueous layer was further extracted with 2 × 100 mL of chloroform. The combined extracts were dried (MgSO₄) and concentrated under reduced pressure. The crude compound was purified by flash chromatography using chloroform/MeOH (95:5) to afford the title compound as a white solid (0.264 g,

-60-

92%). Mp 118-119 °C. ¹H NMR (300 MHz, CDCl₃) ppm 1.68 (s, 2H), 4.12 (s, 2H), 5.77 (s, 2H), 7.30-7.47 (m, 8H), 8.32-8.35 (m, 1H). MS(EI) *m/z* 305 [M⁺]. Anal. Calcd. for C₁₇H₁₅N₃O: C, 66.87; H, 4.95; N, 22.94. Found: C, 67.00; H, 4.82; N, 22.97.

5 Example 52

1-Benzyl-3-[3-(N,N-dimethylaminomethyl)-1,2,4-oxadiazol-5-yl]indazole

Hydroxylamine hydrochloride (1.24 g 17.8 mmol) was added to a solution of sodium (0.64 g, 26 mmol) in MeOH (100 mL). The reaction mixture was stirred at 25 °C for 15 min then dimethylaminoacetonitrile (1.5 g, 17.8 mmol) in MeOH (5 mL) was added and the reaction mixture stirred at 25 °C for a further 5 days. The solid was removed by filtration and the liquid concentrated under reduced pressure. The crude material was taken up in dry THF (100 mL) and sodium hydride (0.114 g, 60%, 2.86 mmol) was added and the reaction mixture was heated to 50 °C. 1-Benzylindazole-3-carboxylic acid methyl ester (0.25 g, 0.938 mmol) was added and the reaction mixture was heated at reflux for 4 h. The THF was removed under reduced pressure and the residue partitioned between chloroform (100 mL) and H₂O (100 mL). The chloroform layer was separated and the aqueous layer was further extracted with 2 × 100 mL of chloroform. The combined extracts were dried (MgSO₄) and concentrated under reduced pressure. The crude compound was purified by flash chromatography using chloroform/MeOH (97.5:2.5) to afford the title compound (0.151 g, 48%) as a yellow solid. Mp 93-95 °C. ¹H NMR (300 MHz, CDCl₃) ppm 2.40 (s, 6H), 3.77 (s, 2H), 5.68 (s, 2H), 7.19-7.37 (m, 8H), 8.27-8.30 (m, 2H). MS(FAB) *m/z* 334 [M+H]⁺. HRMS Calcd. for C₁₉H₂₀N₅O: 334.1668. Found: 334.1655 [M+H]⁺.

25 Example 53

Biological assay

The effectiveness of the compounds of the present invention as sodium channel blockers were investigated in an assay measuring how they inhibit the flux of [¹⁴C]-labelled guanidine through sodium channels, as described in Pauwels, P. J., Leysen, J.E., Laduron, P.M. [³H]Batrachotoxinin A 20-α-benzoate binding to sodium

-61-

channels in rat brain: characterization and pharmacological significance. *Eur. J. Pharmacol.*, 1986, 124, 291-298. The data is presented below in Table 1, expressed as IC_{50} values in μM .

TABLE 1

	Compound	Example No	Guanidine Flux
	1-Benzyl-3-(5-hydroxymethyl-2-furyl)-1H-indazole	4	17
5	1-Benzyl-3-(5-methoxycarbonyl-2-furyl)-1H-indazole	3	15.5
	1-Benzyl-3-[3-aminomethyl-1,2,4-oxadiazol-5-yl]indazole	51	22.4
	1-Benzyl-3-(5-hydroxylaminocarbonyl-2-furyl)-1H-indazole	6	30.9
10	1-Benzyl-3[3-(N,N-dimethylaminomethyl)-1,2,4-oxadiazol-5-yl]indazole	52	33.9
	2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid N'-(3-chlorophenylcarbamoyl) hydrazide		5.8
15	2-{5-[5-tert-Butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl}-1-(4-chloro-phenyl)-ethanone		4.6
	3-Benzylsulfanyl-5-[5-tert-butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-methyl-4H-[1,2,4]triazole		12.3
20	2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid (4-chloro-phenyl)-amide		4.4
	[N-Ethyl-(4-Aminobutyl)]-1-benzylindazole	46	15.5
	1-Benzyl-3-[N-(2-N,N-dimethylaminoethyl) carboxamido]indazole	47	63.01
25	5-(1-Benzyl-1H-indazol-3-yl)-furan-2-carboxylic acid benzyl-hydroxy-amide AND 5-(1-benzyl-1H-indazol-3-yl)-furan-2-carboxylic acid N-benzylhydroxylamine ester	8	3.9
	2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid phenylamide	9	<9
30	2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid benzylamide	10	7
	1-(4-Chloro-phenyl)-5-phenyl-1H-pyrazole-3-carboxylic acid phenylamide	11	18

	5- <i>tert</i> -Butyl-2-(2,4-dichloro-benzyl)-2 <i>H</i> -pyrazole-3-carboxylic acid (4-methoxy-phenyl)-amide	12	<9
	2-Ethyl-5-thiophen-2-yl-2 <i>H</i> -pyrazole-3-carboxylic acid (4-chloro-phenyl)-amide	13	17
5	(<i>S</i>)-5- <i>tert</i> -Butyl-2-(2,4-dichloro-benzyl)-2 <i>H</i> -pyrazole-3-carboxylic acid (4-chloro-phenyl)-amide	14	29
	5- <i>tert</i> -Butyl-2-(2,4-dichloro-benzyl)-2 <i>H</i> -pyrazole-3-carboxylic acid phenethyl-amide	15	10
10	(<i>S</i>)-2-Ethyl-5-thiophen-2-yl-2 <i>H</i> -pyrazole-3-carboxylic acid phenethyl-amide	16	13
	5- <i>tert</i> -Butyl-2-(2,4-dichloro-benzyl)-2 <i>H</i> -pyrazole-3-carboxylic acid phenylamide	17	10
	5- <i>tert</i> -Butyl-2-(2,4-dichloro-benzyl)-2 <i>H</i> -pyrazole-3-carboxylic acid benzylamide	18	9
19	1-(4-Chloro-phenyl)-5-phenyl-1 <i>H</i> -pyrazole-3-carboxylic acid (4-dimethylamino-phenyl)-amide	19	5
	1-(4-Chloro-phenyl)-5-phenyl-1 <i>H</i> -pyrazole-3-carboxylic acid (4- <i>tert</i> -butyl-phenyl)-amide	20	20
20	2- <i>tert</i> -Butyl-5-methyl-2 <i>H</i> -pyrazole-3-carboxylic acid (4- <i>tert</i> -butyl-phenyl)-amide	21	<9
	2- <i>tert</i> -Butyl-5-methyl-2 <i>H</i> -pyrazole-3-carboxylic acid (3,4-dichloro-phenyl)-amide	22	<9
	5- <i>tert</i> -Butyl-2-methyl-2 <i>H</i> -pyrazole-3-carboxylic acid (3,4-dichloro-phenyl)-amide	23	<9
25	2-Benzyl-5- <i>tert</i> -butyl-2 <i>H</i> -pyrazole-3-carboxylic acid (3,4-dichloro-phenyl)-amide	24	<9
	2-Benzyl-5- <i>tert</i> -butyl-2 <i>H</i> -pyrazole-3-carboxylic acid (4- <i>tert</i> -butylphenyl)-amide	25	18
30	5- <i>tert</i> -Butyl-2-methyl-2 <i>H</i> -pyrazole-3-carboxylic acid (4- <i>tert</i> -butyl-phenyl)-amide	26	<9
	2-Benzyl-5- <i>tert</i> -butyl-2 <i>H</i> -pyrazole-3-carboxylic acid (4-dimethylamino-phenyl)-amide	27	<9
	2-Benzyl-5- <i>tert</i> -butyl-2 <i>H</i> -pyrazole-3-carboxylic acid (3-oxazol-5-yl-phenyl)-amide	28	<9

	5- <i>tert</i> -Butyl-2-methyl-2 <i>H</i> -pyrazole-3-carboxylic acid (3-oxazol-5-yl-phenyl)-amide	29	9
	1-(4-Chloro-phenyl)-5-phenyl-1 <i>H</i> -pyrazole-3-carboxylic acid (5- <i>tert</i> -butyl-isoxazol-3-yl)-amide	30	15
5	2- <i>tert</i> -Butyl-5-methyl-2 <i>H</i> -pyrazole-3-carboxylic acid (4-phenylcarbamoyl-phenyl)-amide	31	22
	2-Benzyl-5- <i>tert</i> -butyl-2 <i>H</i> -pyrazole-3-carboxylic acid (3-phenylcarbamoyl-phenyl)-amide	32	22
10	5- <i>tert</i> -Butyl-2-methyl-2 <i>H</i> -pyrazole-3-carboxylic acid (3-phenylcarbamoyl-phenyl)-amide	33	22
	2-Benzyl-5- <i>tert</i> -butyl-2 <i>H</i> -pyrazole-3-carboxylic acid (6-chloro-pyridin-3-yl)-amide	34	<9
	1- <i>tert</i> -Butyl-5-methyl-1 <i>H</i> -pyrazole-3-carboxylic acid (6-chloro-pyridin-3-yl)-amide	35	5
15	1- <i>tert</i> -Butyl-5-methyl-1 <i>H</i> -pyrazole-3-carboxylic acid (4-acetylamino-phenyl)-amide	36	23
	1- <i>tert</i> -Butyl-5-methyl-1 <i>H</i> -pyrazole-3-carboxylic acid (3-benzyloxy-pyridin-2-yl)-amide	37	<9
20	5-Methyl-1-(4-methyl-benzyl)-1 <i>H</i> -pyrazole-3-carboxylic acid (4-acetylamino-phenyl)-amide	38	14
	5- <i>tert</i> -Butyl-2-(2,4-dichloro-benzyl)-2 <i>H</i> -pyrazole-3-carboxylic acid (4-acetylamino-phenyl)-amide	39	24
	2-Ethyl-5-thiophen-2-yl-2 <i>H</i> -pyrazole-3-carboxylic acid (4-acetylamino-phenyl)-amide	40	<9
25	5- <i>tert</i> -Butyl-2-(2,4-dichloro-benzyl)-2 <i>H</i> -pyrazole-3-carboxylic acid (4-(pyridin-3-yl) thiazol-2-yl)-amide	41	14
	2-Ethyl-5-thiophen-2-yl-2 <i>H</i> -pyrazole-3-carboxylic acid (4-(pyridin-3-yl) thiazol-2-yl)-amide.	42	<9
30	2-Benzyl-5- <i>tert</i> -butyl-2 <i>H</i> -pyrazole-3-carboxylic acid (4-acetylamino-phenyl)-amide	43	16
	5- <i>tert</i> -Butyl-2-methyl-2 <i>H</i> -pyrazole-3-carboxylic acid (4-(pyridin-3-yl) thiazol-2-yl)-amide.	44	<9
	5- <i>tert</i> -Butyl-2-methyl-2 <i>H</i> -pyrazole-3-carboxylic acid [3-(4-methoxy-benzyl)-[1,2,4]oxadiazol-5-yl]-amide	45	19

-65-

	3-(Benzylthio)-5-(1-ethyl-3-methyl-1H-pyrazol-5-yl)-4-phenyl-4H-1,2,4-triazolehemihydrate		20
	5-[3-(tert-Butyl)-1-(3-methylbenzyl)pyrazol-5-yl]-4-cyclohexyl-1,2,4-triazole-3-thiol		<9
5	5-[3-tert-Butyl-1-(2,4-dichlorobenzyl)pyrazol-5-yl]-4-methyltriazole-3-thiol		<9
	Ethyl 2-([5-[3-(tert-butyl)-1-(3-methylbenzyl)-1H-pyrazol-5-yl]-4-cyclohexyl-4H-1,2,4-triazol-3-yl]thio)acetate		<9
10	3-[3-(tert-Butyl)-1-(2,4-dichlorobenzyl)-1H-pyrazol-5-yl]-4-phenyl-5-(prop-2-ynylthio)-4H-1,2,4-triazole		18
	3-Benzylsulfanyl-5-[5-tert-butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-methyl-4H-[1,2,4]triazole		12
15	2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid <i>p</i> -tolylamide		2
	2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid (4-bromo-3-chloro-phenyl)-amide		3
	1-tert-Butyl-5-methyl-1H-pyrazole-3-carboxylic acid (4-tert-butyl-phenyl)-amide		6
20	5-tert-Butyl-2-methyl-2H-pyrazole-3-carboxylic acid (4-chloro-phenyl)-amide		6
	5-tert-Butyl-2-methyl-2H-pyrazole-3-carboxylic acid (4-tert-butyl-phenyl)-amide		2
25	5-Methyl-2-(4-methyl-benzyl)-2H-pyrazole-3-carboxylic acid (3-trifluoromethyl-phenyl)-amide		6
	5-Methyl-1-(4-methyl-benzyl)-1H-pyrazole-3-carboxylic acid phenylamide		23
	1-(2,6-Dichloro-benzyl)-5-methyl-1H-pyrazole-3-carboxylic acid <i>m</i> -tolylamide		7
30	2-{5-[5-tert-Butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl}-1-phenyl-ethanone		19.5

-66-

	1-{5-[5- <i>tert</i> -Butyl-2-(4-fluoro-benzyl)-2 <i>H</i> -pyrazol-3-yl]-4-methyl-4 <i>H</i> -[1,2,4]triazol-3-ylsulfanyl}-3,3-dimethyl-butan-2-one		13
5	2-Benzyl-5- <i>tert</i> -butyl-2 <i>H</i> -pyrazole-3-carboxylic acid N'-(3-trifluoromethylphenylcarbamoyl)hydrazide		0.5

Example 54

The neuroprotective effect of the compounds of the invention on the optic nerve was assessed as follows.

Methods*Optic nerve pathology.*

Optic nerves were excised from adult Wistar rats (weighing 240-280 g) after decapitation. They comprised lengths of nerve (each about 9 mm long) running from immediately behind the eyeball to just in front of the optic chiasm. The nerves were incubated in Erlenmeyer flasks (50 ml capacity) containing 20 ml of an artificial CSF (aCSF) solution composed of (mM): NaCl (120), KCl (2.0), CaCl₂ (2.0), NaHCO₃ (26), KH₂PO₄ (1.18), MgSO₄ (1.19) and glucose (11), continuously gassed with 95% O₂/5% CO₂. The flasks were held in a shaking water bath at 37°C.

After 1-2 h preincubation in aCSF, test nerves received the NO donor, PAPA/NO (1 mM) for 2 h or OGD was imposed by transferring the nerves for 1 h into aCSF lacking glucose and gassed with 5% CO₂ in N₂. Afterwards, the nerves were allowed a 90 min recovery period in aCSF. Putative protectant drugs were present from 15 min before until 15 min after the NO exposure or OGD.

The nerves were then fixed for 2 h in a mixture of 4% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4), and post-fixed with 1% osmium tetroxide for 1 h. After dehydration the tissues were embedded in Durcupan resin. Semithin (1 µm) sections were stained with either toluidine blue.

To quantify the extent of axonal pathology under the light microscope, the

-67-

degree of distension of the axon profiles was measured using an image analysis system as described previously (Garthwaite *et al.*, (1999), *Neuroscience*, **94**, 1219-1230). The data are expressed as mean number of axons greater than 2.5 μm in diameter per $10^4 \mu\text{m}^2$ (\pm S.E.M.) in fields from 5-39 nerves.

5

Guanidium ion influx assay

Results

1. Protection of optic nerve

10

Histological examination showed that NO caused extensive axonal degeneration. Quantitative morphometry of the index of axonopathy (the density of axons of diameter greater than 2.5 μm) indicated a 10-fold increase over control nerves (Table 2). The pathology was eliminated by the classical sodium channel blocker, tetrodotoxin, and by BW619C89, a neuroprotective sodium channel inhibitor. A compound of the invention (3-(5'-hydroxymethyl-2-furyl)-1-benzylindazole) was as effective as both these other agents.

15

Tests were also carried out to determine if the compound of the invention could also protect against axonal damage caused by severe oxygen- and glucose-deprivation (OGD). As indicated in Table 2, this procedure resulted in an index of axonopathy somewhat greater than that induced by NO and both BW619C89 and the compound of the invention were able to protect to an equivalent degree.

20

Table 2

25

Treatment	Index of Axonopathy	n
None	23 \pm 3	9
PAPA/NO (1 mM)	226 \pm 22	10
+ Tetrodotoxin (1 μM)	17 \pm 4	4
+ BW619C89 (100 μM)	26 \pm 3	4
+ compound of invention (30 μM)	24 \pm 4	7
OGD	260 \pm 6	4

30

-68-

+ BW619C89 (100 μ M)	53 \pm 5	3
+ compound of invention	72 \pm 15	3

5 Example 55

A further assay was conducted to assess the neuroprotective effect of the compounds of the invention on the optic nerve as follows.

Preparation

- 10 Nerves were excised from male Wistar rats (weighing 300-350g) after sacrifice by CO₂ and decapitation. Each pair of nerves were transferred to 20ml artificial CSF (aCSF) at 10°C:

120mM NaCl, 2mM KCl, 2mM CaCl₂, 26mM NaHCO₃, 1.18mM
KH₂PO₄, 1.19mMgSO₄, 11mM glucose,

- 15 then gassed with 95% O₂/5% CO₂ in a shaking water bath at 37°C.

Once all nerves were excised, they were randomized (2 nerves per flask) and left to incubate for approx. 1hr.

Oxygen and Glucose Deprivation

- 20 After incubation, relevant concentrations of compounds were added and gassing was continued for a further 15 minutes. OGD was then introduced by transferring the nerves into aCSF lacking glucose (+ compound) and gassing with 5%CO₂ in N₂ for 1hr. Control nerves (plus control + drug) were transferred to normal aCSF and gassed with O₂/CO₂ for the same interval.

- 25 All nerves were then re-introduced to O₂/CO₂ gassing and normal aCSF (+ compound). After 15 minutes the nerves were transferred to normal aCSF (- compound) for a further 75 minutes.

A sufficient amount of aCSF was warmed and IBMX (22mg/100ml) was added and left to dissolve (approx. 1hr).

Cyclic GMP accumulation

The neuroprotective effect of the compounds of the invention was determined by establishing the amount of cGMP accumulation in the nerves. To to this, all nerves were transferred to aCSF containing IBMX for 10 minutes. After this time they were
 5 then exposed to 100 μ M DEA/NO for 5 mins then inactivated in 200 μ l boiling hypotonic buffer. Protein and cGMP contents were then measured

Example:

10	Flask	Title	\pm OGD	Amount of compound (dissolved in DMSO)	[DEA/NO]
	1	Control	-	-	100 μ M
	2	OGD	+	-	100 μ M
	3	OGD + 1 μ M compd	+	20 μ l 1mM compound	100 μ M
	4	OGD + 3 μ M compd	+	20 μ l 3mM compound	100 μ M
15	5	OGD + 10 μ M compd	+	20 μ l 10mM compound	100 μ M
	6	OGD + 30 μ M compd	+	20 μ l 30mM compound	100 μ M
	7	OGD + 100 μ M compd	+	20 μ l 100mM compound	100 μ M
	8	OGD + 1 μ M TTX	+	20 μ l 1mM TTX citrate	100 μ M

20 Results

The Table below sets out the results achieved with 30 μ M of each drug. Results are given in terms of the % protection achieved. These were derived by comparing the protection achieved by each drug with that achieved by TTX. TTX would, of
 25 course, be expected to provide substantially complete protection against OGD insult in this assay, as it shuts down all sodium channel activity.

30	<i>Compound</i>	<i>% protection accorded</i>
	2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid p-tolylamide	66
	1-tert-Butyl-5-methyl-1H-pyrazole-3-carboxylic acid (4-tert-butyl-phenyl)-amide	39


-70-

	5- <i>tert</i> -Butyl-2-methyl-2 <i>H</i> -pyrazole-3-carboxylic acid (4-chloro-phenyl)-amide	62
	5- <i>tert</i> -Butyl-2-methyl-2 <i>H</i> -pyrazole-3-carboxylic acid (4- <i>tert</i> -butyl-phenyl)-amide	18
5	1-(2,6-Dichloro-benzyl)-5-methyl-1 <i>H</i> -pyrazole-3-carboxylic acid <i>m</i> -tolylamide	29
	2-{5-[5- <i>tert</i> -Butyl-2-(4-fluoro-benzyl)-2 <i>H</i> -pyrazol-3-yl]-4-methyl-4 <i>H</i> -[1,2,4]triazol-3-ylsulfanyl}-1-phenyl-ethanone	18
10	2-Benzyl-5- <i>tert</i> -butyl-2 <i>H</i> -pyrazole-3-carboxylic acid <i>N'</i> -(3-chlorophenylcarbamoyl) hydrazide	12
	2-{5-[5- <i>tert</i> -Butyl-2-(4-fluoro-benzyl)-2 <i>H</i> -pyrazol-3-yl]-4-methyl-4 <i>H</i> -[1,2,4]triazol-3-ylsulfanyl}-1-(4-chloro-phenyl)-ethanone	19
15	3-Benzylsulfanyl-5-[5- <i>tert</i> -butyl-2-(4-fluoro-benzyl)-2 <i>H</i> -pyrazol-3-yl]-4-methyl-4 <i>H</i> -[1,2,4]triazole	72

-71-

CLAIMS

1. Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in blockading voltage-dependent sodium channels



wherein:


- R_1 is hydrogen, C_1 - C_6 alkyl, aryl or $-(C_1$ - C_6 alkyl)-aryl;
 - R_2 is aryl, heteroaryl, 3- to 6- membered heterocyclyl, C_3 - C_6 carbocyclyl or -XR wherein X is a divalent C_1 - C_6 alkyl, C_2 - C_6 alkenyl or C_2 - C_6 alkynyl group and R is aryl, heteroaryl, 3- to 6- membered heterocyclyl or C_3 - C_6 carbocyclyl, or R_2 is C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl or -COR, -CONR'R'' or -CO₂R' wherein each R' and R'' is the same or different and is selected from hydrogen, C_1 - C_6 alkyl, aryl and heteroaryl and R is selected from C_1 - C_6 alkyl, aryl and heteroaryl; and
 - either R_3 and R_4 , together with the carbon atoms to which they are attached, form a phenyl group, or R_3 and R_4 are the same or different and are selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, aryl, heteroaryl, 3- to 6- membered heterocyclyl, -COR, -CONR'-NR''COR, -CONR'-NR''CS-R, -CO₂R', -CONR'-NR''-CO₂R', -CONR'-NR''-CS-OR', -CONR'R'', -CONR'-NR''CO-NR'''R'''' and -CONR'-NR''CS-NR'''R''''', wherein each R is the same or different and is selected from C_1 - C_6 alkyl, aryl, $-(C_1$ - C_6 alkyl)-aryl and heteroaryl and each R', R'', R''' and R'''' is the same or different and is selected from hydrogen, C_1 - C_6 alkyl, aryl, $-(C_1$ - C_6 alkyl)-aryl and heteroaryl.
2. Use according to claim 1 wherein R_1 is C_1 - C_6 alkyl, aryl or $-(C_1$ - C_6 alkyl)-

-72-

aryl.

3. Use according to claim 2 wherein R_1 is C_1 - C_6 alkyl, phenyl or benzyl.
4. Use according to any one of the preceding claims, wherein R_2 is aryl, heteroaryl, 3- to 6- membered heterocyclyl, C_3 - C_6 carbocyclyl, C_1 - C_6 alkyl,
- 5 C_2 - C_6 alkenyl, $-\text{CONR}'\text{R}''$ or $-\text{CO}_2\text{R}'$ wherein R' and R'' are the same or different and are selected from hydrogen, C_1 - C_6 alkyl, aryl and heteroaryl.
5. Use according to claim 4, wherein R_2 is aryl, heteroaryl, 3- to 6- membered heterocyclyl, C_1 - C_6 alkyl or $-\text{CONR}'\text{R}''$ wherein R' and R'' are the same or different and are selected from hydrogen, C_1 - C_6 alkyl, aryl and heteroaryl.
- 10 6. Use according to any one of the preceding claims, wherein R_3 is hydrogen.
7. Use according to any one of the preceding claims, wherein R_4 is C_1 - C_6 alkyl, aryl, heteroaryl, $-\text{CONR}'\text{-NR}''\text{COR}$, $-\text{CONR}'\text{-NR}''\text{CS-R}$, $-\text{CO}_2\text{R}'$, $-\text{CONR}'\text{R}''$, $-\text{CONR}'\text{-NR}''\text{CO-NR}'''\text{R}''''$ or $-\text{CONR}'\text{-NR}''\text{CS-NR}'''\text{R}''''$ wherein each R is the same or different and is selected from C_1 - C_6 alkyl, aryl, $-(C_1$ - C_6 alkyl)-aryl and heteroaryl and
- 15 each R' , R'' , R''' and R'''' is the same or different and is selected from hydrogen, C_1 - C_6 alkyl, aryl, $-(C_1$ - C_6 alkyl)-aryl and heteroaryl.
8. Use according to claim 7, wherein R_4 is C_1 - C_6 alkyl, heteroaryl, $-\text{CONR}'\text{-NR}''\text{COR}$, $-\text{CONR}'\text{R}''$, $-\text{CONR}'\text{-NR}''\text{CO-NR}'''\text{R}''''$ or $-\text{CONR}'\text{-NR}''\text{CS-NR}'''\text{R}''''$ wherein R is C_1 - C_6 alkyl or aryl and each R' , R'' , R''' and R'''' is the same or different
- 20 and is selected from hydrogen, C_1 - C_6 alkyl, aryl, $-(C_1$ - C_6 alkyl)-aryl and heteroaryl.
9. Use according to any one of claims 1 to 5, wherein the compound of formula (I) is a compound of formula (Ia)

25



wherein R_1 and R_2 are as defined in any one of claims 1 to 5 and Z is one or more


30 selected from hydrogen, C_1 - C_6 alkyl, halogen, hydroxy, C_1 - C_6 alkoxy and $-\text{NR}'\text{R}''$

-73-

wherein R' and R'' are the same or different and are selected from hydrogen and C₁-C₆ alkyl.

10. Use according to claim 1, wherein the compound of formula (I) is a compound of formula (Ib)

5




10 wherein:

- R₁ and R₂ are as defined in any one of claims 1 to 5;
 - A is hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, aryl, heteroaryl, 3- to 6-membered heterocyclyl or C₃-C₆ carbocyclyl; and
 - B is hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₁-C₆ alkynyl, aryl, heteroaryl, -XY
- 15 wherein X is a divalent C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl group and Y is an aryl or heteroaryl group or -X'-COR or -X'-CO₂R wherein X' is a divalent C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl group and R is C₁-C₆ alkyl, aryl or heteroaryl.

11. Use according to claim 1, wherein the compound of formula (I) is a compound of formula (Ic)

20



25


wherein:

- R₁ and R₄ are as defined in any one of claims 1 to 3, 7 and 8; and
- C is aryl, heteroaryl, 3- to 6-membered heterocyclyl or C₃-C₆ carbocyclyl.

12. Use according to claim 1, wherein the compound of formula (I) is a compound of formula (Id)

30

-74-



5 wherein:

- R_1 and R_2 are as defined in any one of claims 1 to 5; and
- D is aryl, heteroaryl, 3- to 6-membered heterocyclyl, C_3 - C_6 carbocyclyl, -XY wherein X is a divalent C_1 - C_6 alkyl, C_2 - C_6 alkenyl or C_2 - C_6 alkynyl group and Y is aryl, heteroaryl, 3- to 6-membered heterocyclyl or C_3 - C_6 carbocyclyl, or -NR''CO-NR'''R'''' wherein R'' and R''' are the same or different and are hydrogen or C_1 - C_6 alkyl and R'''' is hydrogen, C_1 - C_6 alkyl or aryl.

13. Use of a compound of formula (I), as defined in any one of the preceding claims, or a pharmaceutically acceptable salt thereof, in the manufacture of a
 15 medicament for use in protecting neuronal white matter.

14. Use according to any one of the preceding claims, wherein the medicament is for use in protecting ganglion cells and axons of the optic nerve from damage.

15. Use according to claim 14, wherein the damage is caused by NO.

16. Use according to any one of the preceding claims, wherein the medicament is
 20 for use in the treatment or prevention of normal tension glaucoma or multiple sclerosis.

17. A compound of formula (I), as defined in any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, for use in the treatment of the human or animal body by therapy, excluding

- 25 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole
- 1-Benzyl-1-3-(5''-methoxycarbonylfuryl)-indazole
- 1-Benzyl-3-(5''-methoxycarbonyl-2-furyl)-6-methylindazole
- 1-Benzyl-3-(5''-methoxycarbonyl-2-furyl)-6-methoxyindazole
- 1-Benzyl-3-(5''-methoxycarbonyl-2-furyl)-6-fluoroindazole
- 30 1-Benzyl-3-(p-ethoxycarbonylphenyl)indazole

-75-

- 1-Benzyl-3-(5''-hydroxycarbonyl-2-furyl)-indazole
- 1-Benzyl-3-(5''-hydroxycarbonylfuryl-6-methylindazole
- 1-Benzyl-3-(5''-hydroxycarbonylfuryl)-6-methoxyindazole
- 1-Benzyl-3-(5''-hydroxycarbonylfuryl)-6-fluoroindazole
- 5 1-Benzyl-3-(5''-hydroxycarbonylfuryl)-indazole
- 1-Benzyl-3-(5''-hydroxymethylfuryl)-indazole
- 1-Benzyl-3-(5''-hydroxymethylfuryl)-6-methylindazole
- 1-Benzyl-3-(5''-hydroxymethylfuryl)-6-methoxyindazole
- 1-Benzyl-3-(5''-hydroxymethylfuryl)-6-fluoroindazole
- 10 1-Benzyl-3-(p-hydroxymethylphenyl)indazole
- 1-(2-Fluorobenzyl)-3-(5-hydroxymethylfuran-2-yl)indazole
- 1-(2-Methoxybenzyl)-3-(5-hydroxymethylfuran-2-yl)-indazole
- 1-(4-Methoxybenzyl)-3-(5-hydroxymethylfuran-2-yl)-indazole
- 3-(5-(1,3-Dioxolan-2-yl)furan-2-yl)indazole
- 15 1-(2-Cyanobenzyl)-3-(5-(1,3-dioxolan-2-yl)furan-2-yl)-indazole
- 1-(2-Cyanobenzyl)-3-(5-formyl-2-furanyl)-indazole
- 1-(2-Cyanobenzyl)-3-(5-hydroxymethylfuran-2-yl)-indazole
- 1-Benzyl-3-[5-(1,3-dioxolan-2-yl)-furan-2-yl]-indazole
- 1-Benzyl-3-(5-formylfuran-2-yl)-indazole
- 20 1-[5-(1-Benzylindazole-3-yl)-furan-2-yl]-ethanol
- 3-(5-Acetylfuran-2-yl)-1-benzyl-indazole
- 3-(5-Azidomethylfuran-2-yl)-1-benzyl-indazole
- 3-(5-Aminomethylfuran-2-yl)-1-benzyl-indazole
- 1-Benzyl-3-(5-nitrofuran-2-yl)-indazole
- 25 5-[1-(2-Nitro-benzyl)-1H-indazol-3-yl]-furan-2-carbaldehyde
- 3-[3-(5-Formyl-furan-2-yl)-indazol-1-ylmethyl]-benzonitrile
- 5-[1-(4-Fluoro-benzyl)-1H-indazol-3-yl]-furan-2-carbaldehyde
- 1-(2,4-Dichloro-benzyl)-3-(5-[1,3]dioxan-2-yl-furan-2-yl)-1H-indazole
- 3-(5-[1,3]Dioxan-2-yl-furan-2-yl)-1-(4-fluoro-benzyl)-1H-indazole
- 30 Acetic acid 5-(1-benzyl-1H-indazol-3-yl)-furan-2-ylmethyl ester

-76-

- 1-Benzyl-3-[5-(tert-butyl-dimethyl-silanyloxymethyl)-furan-2-yl]-1H-indazole
- E-5-(1-Benzyl-1H-indazol-3-yl)-furan-2-carbaldehyde oxime
- 5-(1-Benzyl-6-methoxy-1H-indazol-3-yl)-furan-2-carbaldehyde
- 5 Acetic acid 5-(1-benzyl-6-methoxy-1H-indazol-3-yl)-furan-2-ylmethyl ester
- 5-[1-(2,4-Dichloro-benzyl)-1H-indazol-3-yl]-furan-2-carbaldehyde
- 5-[1-(3,5-Dimethyl-benzyl)-1H-indazol-3-yl]-furan-2-carbaldehyde
- 5-(1-Benzyl-1H-indazol-3-yl)-thiophene-2-carbaldehyde
- 5-(1-Benzyl-6-methoxy-1H-indazol-3-yl)-furan-2-carbaldehyde oxime
- 10 5-(1-Benzyl-1H-indazol-3-yl)-furan-2-carbaldehyde oxime
- 4-[3-(5-Formyl-furan-2-yl)-indazol-1-ylmethyl]-benzonitrile
- 5-[1-(2-Fluoro-benzyl)-1H-indazol-3-yl]-furan-2-carbaldehyde
- 1-Benzyl-3-(5-oxiranylmethoxymethyl-furan-2-yl)-1H-indazole
- 1-Benzyl-3-(5-methoxymethoxymethyl-furan-2-yl)-1H-indazole, and
- 15 5-[1-(3-Methoxy-benzyl)-1H-indazol-3-yl]-furan-2-carbaldehyde
18. A compound of formula (I), as defined in claim 17, or a pharmaceutically acceptable salt thereof, excluding
- 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid N'-(3-chlorophenylcarbamoyl) hydrazide
- 20 2-{5-[5-tert-Butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-methyl-4H-[1,2,4]triazol-3-ylsulfanyl}-1-(4-chloro-phenyl)-ethanone
- 3-Benzylsulfanyl-5-[5-tert-butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-methyl-4H-[1,2,4]triazole
- 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid (4-chloro-phenyl)-amide
- 25 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid (4-chloro-phenyl)-amide
- 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid (2-chloro-phenyl)-amide
- 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid p-tolylamide
- 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid (4-bromo-3-chloro-phenyl)-amide
- 30

-77-

- 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid N'-[1-(4-chloro-phenyl)-methanoyl]-hydrazide
- 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid N'-(phenylcarbamoyl)hydrazide
- 5 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid N'-(3-chlorobenzoyl)hydrazide
- 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid amide
- 1-tert-Butyl-5-methyl-1H-pyrazole-3-carboxylic acid (4-chloro-phenyl)-amide
- 10 1-tert-Butyl-5-methyl-1H-pyrazole-3-carboxylic acid (4-tert-butyl-phenyl)-amide
- 5-tert-Butyl-2-methyl-2H-pyrazole-3-carboxylic acid phenylamide
- 5-tert-Butyl-2-methyl-2H-pyrazole-3-carboxylic acid (4-chloro-phenyl)-amide
- 15 5-tert-Butyl-2-methyl-2H-pyrazole-3-carboxylic acid (4-tert-butyl-phenyl)-amide
- 5-Methyl-2-(4-methyl-benzyl)-2H-pyrazole-3-carboxylic acid (4-chloro-phenyl)-amide
- 5-Methyl-2-(4-methyl-benzyl)-2H-pyrazole-3-carboxylic acid (2-chloro-phenyl)-amide
- 20 5-Methyl-2-(4-methyl-benzyl)-2H-pyrazole-3-carboxylic acid (3-trifluoromethyl-phenyl)-amide
- 5-Methyl-2-(4-methyl-benzyl)-2H-pyrazole-3-carboxylic acid p-tolylamide
- 5-Methyl-2-(3-trifluoromethyl-benzyl)-2H-pyrazole-3-carboxylic acid (2,4-dichloro-phenyl)-amide
- 25 5-Methyl-2-(3-trifluoromethyl-benzyl)-2H-pyrazole-3-carboxylic acid (4-cyclohexyl-phenyl)-amide
- 5-Methyl-1-(4-methyl-benzyl)-1H-pyrazole-3-carboxylic acid (4-bromo-phenyl)-amide
- 30 5-Methyl-1-(4-methyl-benzyl)-1H-pyrazole-3-carboxylic acid phenylamide

-78-

- 1-(2,6-Dichloro-benzyl)-5-methyl-1H-pyrazole-3-carboxylic acid m-
tolylamide
- 1-(2,6-Dichloro-benzyl)-5-methyl-1H-pyrazole-3-carboxylic acid (4-tert-
butyl-phenyl)-amide
- 5 2-[5-(2-Ethyl-5-methyl-2H-pyrazol-3-yl)-4-phenyl-4H-[1,2,4]triazol-3-
ylsulfanyl]-1-phenyl-ethanone
- 2-[4-(4-Chloro-phenyl)-5-(2-ethyl-5-methyl-2H-pyrazol-3-yl)-4H-
[1,2,4]triazol-3-ylsulfanyl]-1-phenyl-ethanone
- 2-[5-(2-Ethyl-5-methyl-2H-pyrazol-3-yl)-4-(3-methoxy-propyl)-4H-
10 [1,2,4]triazol-3-ylsulfanyl]-1-phenyl-ethanone
- 2-[5-(2-Ethyl-5-methyl-2H-pyrazol-3-yl)-4-(3-trifluoromethyl-phenyl)-4H-
[1,2,4]triazol-3-ylsulfanyl]-1-phenyl-ethanone
- 5-[5-tert-Butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-methyl-4H-
[1,2,4]triazole-3-thiol
- 15 3-[5-tert-Butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-methyl-5-
methylsulfanyl-4H-[1,2,4]triazole
- 3-Allylsulfanyl-5-[5-tert-butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-
methyl-4H-[1,2,4]triazole
- 3-Benzylsulfanyl-5-[5-tert-butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-
20 methyl-4H-[1,2,4]triazole
- 2-[5-[5-tert-Butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-methyl-4H-
[1,2,4]triazol-3-ylsulfanyl]-1-phenyl-ethanone
- 2-[5-[5-tert-Butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-methyl-4H-
[1,2,4]triazol-3-ylsulfanyl]-1-(4-chloro-phenyl)-ethanone
- 25 {5-[5-tert-Butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-methyl-4H-[1,2,4]
triazol-3-ylsulfanyl}-acetic acid ethyl ester
- 1-{5-[5-tert-Butyl-2-(4-fluoro-benzyl)-2H-pyrazol-3-yl]-4-methyl-4H-[1,2,4]
triazol-3-ylsulfanyl}-3,3-dimethyl-butan-2-one
- 2-Ethyl-5-methyl-2H-pyrazole-3-carboxylic acid N'-[1-(3-chloro-phenyl)-
30 methanoyl]-hydrazide

-79-

Benzoic acid N'-[1-(2-benzyl-5-tert-butyl-2H-pyrazol-3-yl)-methanoyl]-hydrazide

2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid N'-[1-(4-trifluoromethyl-phenyl)-methanoyl]-hydrazide

5 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid N'-(2,2-dimethylpropanoyl)-hydrazide

2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid N'-(2,6-dimethylphenylcarbamoyl)hydrazide

10 2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid N'-(3-trifluoromethylphenylcarbamoyl)hydrazide

2-Benzyl-5-tert-butyl-2H-pyrazole-3-carboxylic acid N'-(methylthiocarbamoyl)hydrazide

INTERNATIONAL SEARCH REPORT

Interr il Application No
PCT/GB 01/00472

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D405/04 C07D231/14 C07D413/04 C07D409/04 C07D417/04
C07D417/14 C07D401/12 C07D231/56 A61K31/415 A61K31/416
A61K31/4155 A61P25/00 C07D403/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 196 42 323 A (BAYER AG) 16 April 1998 (1998-04-16) cited in the application claim 1	17,18
X	EP 0 667 345 A (YUNG SHIN PHARM IND CO LTD) 16 August 1995 (1995-08-16) cited in the application claim 1	17,18
X	DE 196 42 255 A (BAYER AG) 16 April 1998 (1998-04-16) cited in the application claim 1	17,18
X	EP 0 459 887 A (NOVAPHARME) 4 December 1991 (1991-12-04) claim 1; examples	17,18
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

S document member of the same patent family

Date of the actual completion of the international search

23 April 2001

Date of mailing of the international search report

02/05/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorize 1 officer

De Jong, B

INTERNATIONAL SEARCH REPORT

Intern: Application No

PCT/GB 01/00472

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 462 960 A (BARTH FRANCIS ET AL) 31 October 1995 (1995-10-31) column 3, line 35 - line 48; tables 1,2 -----	17,18
A	DE 198 34 714 A (BOEHRINGER INGELHEIM PHARMA) 3 February 2000 (2000-02-03) page 2, line 67 -----	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

Interr. Application No

PCT/GB 01/00472

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
DE 19642323	A	16-04-1998	AU 4943097 A	11-05-1998
			BR 9712523 A	09-05-2000
			CZ 9901309 A	14-07-1999
			WO 9816507 A	23-04-1998
			EP 0934311 A	11-08-1999
			NO 991732 A	04-06-1999
			PL 332871 A	25-10-1999
			SK 48799 A	14-02-2000
			TR 9901174 T	23-08-1999
			US 6166027 A	26-12-2000
EP 0667345	A	16-08-1995	JP 2928079 B	28-07-1999
			JP 7224057 A	22-08-1995
			US 5574168 A	12-11-1996
			DE 69512444 D	04-11-1999
			DE 69512444 T	09-03-2000
DE 19642255	A	16-04-1998	AU 5049498 A	11-05-1998
			BR 9712304 A	31-08-1999
			CZ 9901292 A	14-07-1999
			WO 9816223 A	23-04-1998
			EP 0932403 A	04-08-1999
			HU 9903885 A	28-11-2000
			JP 2001502318 T	20-02-2001
			NO 991685 A	09-04-1999
			PL 332719 A	11-10-1999
			SK 46599 A	14-02-2000
			TR 9900782 T	21-07-1999
			US 6180656 B	30-01-2001
EP 0459887	A	04-12-1991	FR 2662692 A	06-12-1991
			US 5464860 A	07-11-1995
			US 5258397 A	02-11-1993
US 5462960	A	31-10-1995	FR 2714057 A	23-06-1995
			EP 0658546 A	21-06-1995
			JP 7324076 A	12-12-1995
DE 19834714	A	03-02-2000	AU 5162699 A	28-02-2000
			WO 0007986 A	17-02-2000
			NO 20010513 A	30-01-2001
			US 6051583 A	18-04-2000